{ "instance": { "legn-20f_20211231.htm": { "axisCustom": 0, "axisStandard": 28, "contextCount": 469, "dts": { "calculationLink": { "local": [ "legn-20211231_cal.xml" ] }, "definitionLink": { "local": [ "legn-20211231_def.xml" ] }, "inline": { "local": [ "legn-20f_20211231.htm" ] }, "labelLink": { "local": [ "legn-20211231_lab.xml" ] }, "presentationLink": { "local": [ "legn-20211231_pre.xml" ] }, "schema": { "local": [ "legn-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 931, "entityCount": 1, "hidden": { "http://legendbiotech.com/20211231": 58, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 20, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 84 }, "keyCustom": 228, "keyStandard": 355, "memberCustom": 87, "memberStandard": 42, "nsprefix": "legn", "nsuri": "http://legendbiotech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Issued But Not Yet Effective International Financial Reporting Standards", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIssuedButNotYetEffectiveInternationalFinancialReportingStandards", "shortName": "Issued But Not Yet Effective International Financial Reporting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DetailedDisclosureOfTaxCharges", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Income Tax - Summary of Tax Charges (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails", "shortName": "Income Tax - Summary of Tax Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DetailedDisclosureOfTaxCharges", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Income Tax - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails", "shortName": "Income Tax - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRate", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "legn:TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRate", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "legn:StatutoryBlendedIncomeTaxRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Income Tax - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Parenthetical) (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesParentheticalDetails", "shortName": "Income Tax - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R103": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101020 - Disclosure - Loss per Share Attributable to Ordinary Equity Holders of the Parent - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentAdditionalInformationDetails", "shortName": "Loss per Share Attributable to Ordinary Equity Holders of the Parent - Additional Information (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Loss per Share Attributable to Ordinary Equity Holders of the Parent - Summary of Calculations of Basic and Diluted Loss per Share (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentSummaryOfCalculationsOfBasicAndDilutedLossPerShareDetails", "shortName": "Loss per Share Attributable to Ordinary Equity Holders of the Parent - Summary of Calculations of Basic and Diluted Loss per Share (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R105": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101040 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20191231", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101050 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_legnLicenseAndCollaborationAgreementMember_20210101_20211231", "decimals": "-5", "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101060 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "shortName": "Intangible Assets - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_20191231", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ValueAddedTaxReceivables", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101070 - Disclosure - Other Non-Current Assets - Summary of Other Non-Current Assets (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails", "shortName": "Other Non-Current Assets - Summary of Other Non-Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherNoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:LesseeLeasingArrangementsLeasesTermDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101080 - Disclosure - Leases - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:LesseeLeasingArrangementsLeasesTermDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Summary Of Significant Accounting Policies", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary Of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101090 - Disclosure - Leases - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "shortName": "Leases - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20191231", "decimals": "-3", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101100 - Disclosure - Leases - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "shortName": "Leases - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:LesseeLeaseLiabilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "legn:IncreaseInLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101110 - Disclosure - Leases - Summary of Lease Expense (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpenseDetails", "shortName": "Leases - Summary of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101120 - Disclosure - Leases - Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Operating Leases (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails", "shortName": "Leases - Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanOneYearMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210513", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101130 - Disclosure - Convertible Redeemable Preferred Shares - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "shortName": "Convertible Redeemable Preferred Shares - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:DisclosureOfConvertibleRedeemablePreferredSharesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfShareCapitalAxis_legnSeriesAConvertibleRedeemablePreferredSharesMember_20211231", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "ifrs-full:DisclosureOfInventoriesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101140 - Disclosure - Inventories - Summary of Inventories (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails", "shortName": "Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "ifrs-full:DisclosureOfInventoriesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101150 - Disclosure - Trade Receivables - Summary of Trade Receivables (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails", "shortName": "Trade Receivables - Summary of Trade Receivables (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R117": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "INF", "first": true, "lang": null, "name": "legn:PercentageOfConcentrationOfCreditRiskOfTradeReceivablesDueFromOneSingleCustomerUnderLicenseAndCollaborationAgreement", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101160 - Disclosure - Trade Receivables - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails", "shortName": "Trade Receivables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "INF", "first": true, "lang": null, "name": "legn:PercentageOfConcentrationOfCreditRiskOfTradeReceivablesDueFromOneSingleCustomerUnderLicenseAndCollaborationAgreement", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101170 - Disclosure - Trade Receivables - Summary of Movements in Loss Allowance for Impairment of Trade Receivables (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfMovementsInLossAllowanceForImpairmentOfTradeReceivablesDetails", "shortName": "Trade Receivables - Summary of Movements in Loss Allowance for Impairment of Trade Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101180 - Disclosure - Trade Receivables - Summary of Information About Credit Risk Exposure on Group's Trade Receivables Using Provision Matrix (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "shortName": "Trade Receivables - Summary of Information About Credit Risk Exposure on Group's Trade Receivables Using Provision Matrix (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullMaturityAxis_ifrs-fullNotLaterThanThreeMonthsMember_20201231", "decimals": "4", "lang": null, "name": "ifrs-full:ExpectedCreditLossRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Significant Accounting Judgements and Estimates", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimates", "shortName": "Significant Accounting Judgements and Estimates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ValueAddedTaxReceivables", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101190 - Disclosure - Prepayments, Other Receivables and Other Assets - Summary of Prepayments, Other Receivables and Other Assets (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails", "shortName": "Prepayments, Other Receivables and Other Assets - Summary of Prepayments, Other Receivables and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfFinancialInstrumentsAxis_legnPrepaymentsOtherReceivablesAndOtherAssetsMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:InterestReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfFinancialInstrumentsAxis_legnOtherReceivablesMember_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101200 - Disclosure - Prepayments, Other Receivables and Other Assets - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "shortName": "Prepayments, Other Receivables and Other Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R122": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101210 - Disclosure - Financial Assets Measured At Amortized Cost - Summary of Financial Assets Measured at Amortized Cost (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "shortName": "Financial Assets Measured At Amortized Cost - Summary of Financial Assets Measured at Amortized Cost (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R123": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101220 - Disclosure - Financial Assets Measured At Amortized Cost - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "shortName": "Financial Assets Measured At Amortized Cost - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfFinancialAssetsAxis_legnCommercialPaperIssuedByFinancialInstitutionMember_20211231", "decimals": "-5", "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndBankBalancesAtCentralBanks", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101230 - Disclosure - Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails", "shortName": "Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "lang": null, "name": "legn:PledgedShortTermDeposits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndBankBalancesAtCentralBanks", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101240 - Disclosure - Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "shortName": "Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R126": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101250 - Disclosure - Trade and Notes Payables - Summary of Trade and Notes Payables (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails", "shortName": "Trade and Notes Payables - Summary of Trade and Notes Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "lang": null, "name": "legn:NotesPayables", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:TradePayablesTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101260 - Disclosure - Trade and Notes Payables - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails", "shortName": "Trade and Notes Payables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:TradePayablesTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R128": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory", "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:AccruedPayroll", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101270 - Disclosure - Other Payables and Accruals - Summary of Other Payables and Accruals (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails", "shortName": "Other Payables and Accruals - Summary of Other Payables and Accruals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory", "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:AccruedPayroll", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R129": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayablesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101280 - Disclosure - Other Payables and Accruals - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsAdditionalInformationDetails", "shortName": "Other Payables and Accruals - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayablesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Operating Segment Information", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformation", "shortName": "Operating Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R130": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfMovementsInContractLiabilities", "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101290 - Disclosure - Contract Liabilities - Schedule of Details of Contract Liabilities (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "shortName": "Contract Liabilities - Schedule of Details of Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:ScheduleOfContractLiabilities", "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProductsAndServicesAxis_legnJSCServiceMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R131": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfMovementsInContractLiabilities", "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101300 - Disclosure - Contract Liabilities - Summary of Movements in Contract Liabilities (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesSummaryOfMovementsInContractLiabilitiesDetails", "shortName": "Contract Liabilities - Summary of Movements in Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfMovementsInContractLiabilities", "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "legn:ContractLiabilityPaymentsReceivedDueToReceive", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R132": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RetainedEarnings", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101310 - Disclosure - Deferred Tax - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "shortName": "Deferred Tax - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_srtStatementGeographicalAxis_countryHK_20210101_20211231", "decimals": "0", "lang": null, "name": "ifrs-full:DeferredTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R133": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101320 - Disclosure - Deferred Tax - Summary of Items with Respect to, Deferred Tax Assets have not been Recognized (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails", "shortName": "Deferred Tax - Summary of Items with Respect to, Deferred Tax Assets have not been Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R134": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210513", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101330 - Disclosure - Warrant Liability - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "shortName": "Warrant Liability - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210513", "decimals": "INF", "lang": null, "name": "legn:ExercisePricePerOrdinaryShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R135": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatory", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:WarrantLiabilityAssessed", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101340 - Disclosure - Warrant Liability - Schedule of Movement of Warrant Liability (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityScheduleOfMovementOfWarrantLiabilityDetails", "shortName": "Warrant Liability - Schedule of Movement of Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R136": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDeferredGovernmentGrantsExplanatory", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101350 - Disclosure - Government Grants - Summary of Deferred Government Grants (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails", "shortName": "Government Grants - Summary of Deferred Government Grants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDeferredGovernmentGrantsExplanatory", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:GovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R137": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfUnfulfilledConditionsAndOtherContingenciesAttachingToGovernmentAssistance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101360 - Disclosure - Government Grants - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsAdditionalInformationDetails", "shortName": "Government Grants - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfUnfulfilledConditionsAndOtherContingenciesAttachingToGovernmentAssistance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R138": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullBorrowingsByNameAxis_legnThreePointZeroThreeInterestBearingLoansMember_20211231", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:BorrowingsInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101370 - Disclosure - Interest-Bearing Loans and Borrowings - Summary of Interest-Bearing Loans and Borrowings (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails", "shortName": "Interest-Bearing Loans and Borrowings - Summary of Interest-Bearing Loans and Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullBorrowingsByNameAxis_legnThreePointZeroThreeInterestBearingLoansMember_20211231", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:BorrowingsInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R139": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:Borrowings", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101380 - Disclosure - Interest-Bearing Loans and Borrowings - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsAdditionalInformationDetails", "shortName": "Interest-Bearing Loans and Borrowings - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:Borrowings", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Revenue, Other Income and Gains", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGains", "shortName": "Revenue, Other Income and Gains", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R140": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101390 - Disclosure - Share Capital and Share Premium - Summary of Shares (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "shortName": "Share Capital and Share Premium - Summary of Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_20211231", "decimals": "INF", "lang": null, "name": "legn:AuthorizedShareCapital", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R141": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210513", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101400 - Disclosure - Share Capital and Share Premium - Summary of Shares (Parenthetical) (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails", "shortName": "Share Capital and Share Premium - Summary of Shares (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_20211231", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R142": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "-3", "first": true, "lang": null, "name": "legn:ShareCapitalAndSharePremium", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101410 - Disclosure - Share Capital and Share Premium - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "shortName": "Share Capital and Share Premium - Summary of Movements in the Company's Share Capital and Share Premium (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20191231", "decimals": "-3", "lang": null, "name": "legn:ShareCapitalAndSharePremium", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R143": { "firstAnchor": { "ancestors": [ "p", "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210513", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101420 - Disclosure - Share Capital and Share Premium - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "shortName": "Share Capital and Share Premium - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfShareCapitalAxis_ifrs-fullOrdinarySharesMember_20211220_20211220", "decimals": "-5", "lang": null, "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R144": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DateOfGrantOfSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101430 - Disclosure - Share Option Scheme - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "shortName": "Share Option Scheme - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DateOfGrantOfSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R145": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20201231", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101440 - Disclosure - Share Option Scheme - Summary of Share Options Outstanding Under the Scheme (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails", "shortName": "Share Option Scheme - Summary of Share Options Outstanding Under the Scheme (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20181231", "decimals": "4", "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R146": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101450 - Disclosure - Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "shortName": "Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullMaturityAxis_legnTwentyNineteenTwelveTwentyFiveToTwentyTwentySevenTwelveTwentyFiveMember_20211231", "decimals": "0", "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R147": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullCategoriesOfRelatedPartiesAxis_legnGenscriptGroupMember_ifrs-fullMaturityAxis_legnTwoThousandNineteenElevenTwentyNineToTwoThousandNineteenTwelveNineMember_20211231", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101460 - Disclosure - Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Parenthetical) (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails", "shortName": "Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullCategoriesOfRelatedPartiesAxis_legnGenscriptGroupMember_ifrs-fullMaturityAxis_legnTwoThousandNineteenElevenTwentyNineToTwoThousandNineteenTwelveNineMember_20211231", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R148": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "U_legnYear", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101470 - Disclosure - Share Option Scheme - Summary of Fair Value of Equity Settled Share Options Granted (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails", "shortName": "Share Option Scheme - Summary of Fair Value of Equity Settled Share Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "U_legnYear", "xsiNil": "false" } }, "R149": { "firstAnchor": { "ancestors": [ "p", "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20200526_20200526", "decimals": null, "first": true, "lang": "en-US", "name": "legn:RestrictedStockUnitsSchemeTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101480 - Disclosure - Restricted Stock Units - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "shortName": "Restricted Stock Units - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20200526_20200526", "decimals": null, "first": true, "lang": "en-US", "name": "legn:RestrictedStockUnitsSchemeTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:ProfitLossBeforeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Loss Before Tax", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTax", "shortName": "Loss Before Tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:ProfitLossBeforeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R150": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_legnRestrictedStockUnitsMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101490 - Disclosure - Restricted Stock Units - Summary of Movement in Number of RSU Outstanding (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails", "shortName": "Restricted Stock Units - Summary of Movement in Number of RSU Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfSharebasedPaymentArrangementsAxis_legnRestrictedStockUnitsMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R151": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "legn:PaidInCapitalAndReserveFunds", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101500 - Disclosure - Reserves - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureReservesAdditionalInformationDetails", "shortName": "Reserves - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "legn:PaidInCapitalAndReserveFunds", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R152": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "legn:NonCashAdditionToInterestBearingLoansAndBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101510 - Disclosure - Notes to the Consolidated Statement of Cash Flows - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "shortName": "Notes to the Consolidated Statement of Cash Flows - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "legn:NonCashAdditionToInterestBearingLoansAndBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R153": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101520 - Disclosure - Notes to the Consolidated Statement of Cash Flows - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "shortName": "Notes to the Consolidated Statement of Cash Flows - Summary of Changes in Liabilities Arising from Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullComponentsOfEquityAxis_legnConvertibleRedeemablePreferredSharesMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R154": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:CashOutflowForLeasesWithinOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101530 - Disclosure - Notes to the Consolidated Statement of Cash Flows - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails", "shortName": "Notes to the Consolidated Statement of Cash Flows - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:CashOutflowForLeasesWithinOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R155": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfCapitalCommitmentsExplanatory", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:ConstructionPaymentPayableInFuture", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101540 - Disclosure - Commitments and Contingencies - Summary of Capital Commitments (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCapitalCommitmentsDetails", "shortName": "Commitments and Contingencies - Summary of Capital Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfCapitalCommitmentsExplanatory", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:ConstructionPaymentPayableInFuture", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R156": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210901_20210930", "decimals": "-5", "first": true, "lang": null, "name": "legn:FormerEmployeeDamagesDemand", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101550 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210901_20210930", "decimals": "-5", "first": true, "lang": null, "name": "legn:FormerEmployeeDamagesDemand", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R157": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfNatureOfRelatedPartyRelationship", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullCategoriesOfRelatedPartiesAxis_legnNanjingGenScriptBiotechCoLimitedMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfNatureOfRelatedPartyRelationship", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101560 - Disclosure - Related Party Transactions - Summary of Nature of Related Party Relationship (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "shortName": "Related Party Transactions - Summary of Nature of Related Party Relationship (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfNatureOfRelatedPartyRelationship", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullCategoriesOfRelatedPartiesAxis_legnNanjingGenScriptBiotechCoLimitedMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfNatureOfRelatedPartyRelationship", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R158": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101570 - Disclosure - Related Party Transactions - Summary of Transactions with Related Parties (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "shortName": "Related Party Transactions - Summary of Transactions with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesOfGoodsRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R159": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnBorrowings", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101580 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullRangeAxis_ifrs-fullBottomOfRangeMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "legn:LesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:EntireDisclosureOfFinanceCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Finance Costs", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCosts", "shortName": "Finance Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:EntireDisclosureOfFinanceCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R160": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101590 - Disclosure - Related Party Transactions - Summary of Outstanding Balances with Related Parties (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "shortName": "Related Party Transactions - Summary of Outstanding Balances with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullLeaseLiabilitiesMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R161": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101600 - Disclosure - Related Party Transactions - Summary of Compensation of Key Management Personnel (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails", "shortName": "Related Party Transactions - Summary of Compensation of Key Management Personnel (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R162": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101610 - Disclosure - Financial Instruments by Category - Summary of Financial Assets (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails", "shortName": "Financial Instruments by Category - Summary of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfFinancialAssetsAxis_ifrs-fullTradeReceivablesMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialAssetsAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R163": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101620 - Disclosure - Financial Instruments by Category - Summary of Financial Liabilities (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails", "shortName": "Financial Instruments by Category - Summary of Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R164": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101630 - Disclosure - Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails", "shortName": "Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLevelsOfFairValueHierarchyAxis_ifrs-fullLevel2OfFairValueHierarchyMember_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullWarrantyContingentLiabilityMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R165": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatory", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullWarrantyContingentLiabilityMember_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101640 - Disclosure - Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Valuation of Warrant Liability (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "shortName": "Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Valuation of Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatory", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis_ifrs-fullWarrantyContingentLiabilityMember_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R166": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101650 - Disclosure - Fair Value and Fair Value Hierarchy of Financial Instruments - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails", "shortName": "Fair Value and Fair Value Hierarchy of Financial Instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R167": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "legn:PercentageOfForeignCurrencyForwardExchangeContract", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101660 - Disclosure - Financial Risk Management Objectives and Policies - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "shortName": "Financial Risk Management Objectives and Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "legn:PercentageOfForeignCurrencyForwardExchangeContract", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R168": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProbabilityOfDefaultAxis_legnUSDollarStrengthensAgainstRMBMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "legn:PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101670 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails", "shortName": "Financial Risk Management Objectives and Policies - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProbabilityOfDefaultAxis_legnUSDollarStrengthensAgainstRMBMember_ifrs-fullTypesOfRisksAxis_ifrs-fullCurrencyRiskMember_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "legn:PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R169": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:OtherPayablesAndAccrualsCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101680 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "shortName": "Financial Risk Management Objectives and Policies - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfRisksAxis_ifrs-fullLiquidityRiskMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:TradeAndOtherPayables", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Tax", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTax", "shortName": "Income Tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R170": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Liabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101690 - Disclosure - Financial Risk Management Objectives and Policies - Summary of Monitoring Capital Using Gearing Ratio (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "shortName": "Financial Risk Management Objectives and Policies - Summary of Monitoring Capital Using Gearing Ratio (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTypesOfRisksAxis_ifrs-fullEquityPriceRiskMember_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:Liabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Loss per Share Attributable to Ordinary Equity Holders of the Parent", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParent", "shortName": "Loss per Share Attributable to Ordinary Equity Holders of the Parent", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Property, Plant and Equipment", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME", "role": "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Intangible Assets", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Other Non-Current Assets", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssets", "shortName": "Other Non-Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Leases", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfConvertibleRedeemablePreferredSharesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Convertible Redeemable Preferred Shares", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredShares", "shortName": "Convertible Redeemable Preferred Shares", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfConvertibleRedeemablePreferredSharesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Inventories", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Trade Receivables", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivables", "shortName": "Trade Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Prepayments, Other Receivables and Other Assets", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssets", "shortName": "Prepayments, Other Receivables and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Financial Assets Measured At Amortized Cost", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCost", "shortName": "Financial Assets Measured At Amortized Cost", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Cash and Cash Equivalents, Time Deposits and Pledged Deposits", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDeposits", "shortName": "Cash and Cash Equivalents, Time Deposits and Pledged Deposits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Trade and Notes Payables", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayables", "shortName": "Trade and Notes Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "role": "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "lang": null, "name": "legn:AdvancePaymentsForPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Other Payables and Accruals", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccruals", "shortName": "Other Payables and Accruals", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfContractLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Contract Liabilities", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilities", "shortName": "Contract Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfContractLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Deferred Tax", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTax", "shortName": "Deferred Tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfWarrantLiabilityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Warrant Liability", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiability", "shortName": "Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfWarrantLiabilityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Government Grants", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrants", "shortName": "Government Grants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Interest-Bearing Loans and Borrowings", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowings", "shortName": "Interest-Bearing Loans and Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Share Capital and Share Premium", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremium", "shortName": "Share Capital and Share Premium", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Share Option Scheme", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionScheme", "shortName": "Share Option Scheme", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:RestrictedStockUnitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Restricted Stock Units", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnits", "shortName": "Restricted Stock Units", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:RestrictedStockUnitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Reserves", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureReserves", "shortName": "Reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20181231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "role": "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20181231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Notes to the Consolidated Statement of Cash Flows", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlows", "shortName": "Notes to the Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Commitments and Contingencies", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Related Party Transactions", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Financial Instruments by Category", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory", "shortName": "Financial Instruments by Category", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair Value and Fair Value Hierarchy of Financial Instruments", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstruments", "shortName": "Fair Value and Fair Value Hierarchy of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Financial Risk Management Objectives and Policies", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPolicies", "shortName": "Financial Risk Management Objectives and Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Approval of the Consolidated Financial Statements", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureApprovalOfConsolidatedFinancialStatements", "shortName": "Approval of the Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Summary Of Significant Accounting Policies (Policies)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary Of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Corporate Information (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationTables", "shortName": "Corporate Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Summary Of Significant Accounting Policies (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary Of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:RetainedEarnings", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "role": "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Operating Segment Information (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationTables", "shortName": "Operating Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Revenue, Other Income and Gains (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsTables", "shortName": "Revenue, Other Income and Gains (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "legn:ProfitLossBeforeTaxExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingAndCreditingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Loss Before Tax (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxTables", "shortName": "Loss Before Tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:ProfitLossBeforeTaxExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingAndCreditingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Finance Costs (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsTables", "shortName": "Finance Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DetailedDisclosureOfTaxCharges", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Tax (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxTables", "shortName": "Income Tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DetailedDisclosureOfTaxCharges", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Loss per Share Attributable to Ordinary Equity Holders of the Parent (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentTables", "shortName": "Loss per Share Attributable to Ordinary Equity Holders of the Parent (Tables)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Intangible Assets (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Other Non-Current Assets (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsTables", "shortName": "Other Non-Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Leases (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForFinanceIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Inventories (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Trade Receivables (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesTables", "shortName": "Trade Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Prepayments, Other Receivables and Other Assets (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsTables", "shortName": "Prepayments, Other Receivables and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfInformationAboutCondensedFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Financial Assets Measured At Amortized Cost (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostTables", "shortName": "Financial Assets Measured At Amortized Cost (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfInformationAboutCondensedFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTables", "shortName": "Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Trade and Notes Payables (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesTables", "shortName": "Trade and Notes Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfTradeAndOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Other Payables and Accruals (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsTables", "shortName": "Other Payables and Accruals (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfOtherPayablesAndAccrualsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:ScheduleOfContractLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Contract Liabilities (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesTables", "shortName": "Contract Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfContractLiabilities", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:ScheduleOfContractLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Deferred Tax (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxTables", "shortName": "Deferred Tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Warrant Liability (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityTables", "shortName": "Warrant Liability (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:DisclosureOfWarrantLiabilityExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Corporate Information", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformation", "shortName": "Corporate Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDeferredGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Government Grants (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsTables", "shortName": "Government Grants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDeferredGovernmentGrantsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Interest-Bearing Loans and Borrowings (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsTables", "shortName": "Interest-Bearing Loans and Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Share Capital and Share Premium (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumTables", "shortName": "Share Capital and Share Premium (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Share Option Scheme (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeTables", "shortName": "Share Option Scheme (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Restricted Stock Units (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsTables", "shortName": "Restricted Stock Units (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "legn:RestrictedStockUnitsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Notes to the Consolidated Statement of Cash Flows (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsTables", "shortName": "Notes to the Consolidated Statement of Cash Flows (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfCapitalCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfCapitalCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:SummaryOfNatureOfRelatedPartyRelationship", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Related Party Transactions (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:SummaryOfNatureOfRelatedPartyRelationship", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Financial Instruments by Category (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables", "shortName": "Financial Instruments by Category (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Fair Value and Fair Value Hierarchy of Financial Instruments (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsTables", "shortName": "Fair Value and Fair Value Hierarchy of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Basis of Preparation", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureBasisOfPreparation", "shortName": "Basis of Preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Financial Risk Management Objectives and Policies (Tables)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesTables", "shortName": "Financial Risk Management Objectives and Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:AddressOfRegisteredOfficeOfEntity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Corporate Information - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails", "shortName": "Corporate Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:AddressOfRegisteredOfficeOfEntity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Corporate Information - Information About Subsidiaries (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails", "shortName": "Corporate Information - Information About Subsidiaries (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullSignificantInvestmentsInSubsidiariesAxis_legnLegendBiotechLimitedMember_20210101_20211231", "decimals": null, "lang": "en-US", "name": "ifrs-full:NameOfSubsidiary", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_legnFreeholdLandMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis_legnFreeholdLandMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets Amortised on Straight-line Basis over Useful Economic Lives (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails", "shortName": "Summary of Significant Accounting Policies - Intangible Assets Amortised on Straight-line Basis over Useful Economic Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-fullComputerSoftwareMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:AmortisationMethodIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfAssetsAxis_legnLeaseholdLandMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Summary of Significant Accounting Policies - Right-of-use Assets Depreciated on Straight-line Basis over Lease Terms and Estimated Useful Lives (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails", "shortName": "Summary of Significant Accounting Policies - Right-of-use Assets Depreciated on Straight-line Basis over Lease Terms and Estimated Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullClassesOfAssetsAxis_legnLeaseholdLandMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "legn:LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:DeferredTaxAssetNotYetRecognized", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails", "shortName": "Significant Accounting Judgements and Estimates - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-5", "lang": null, "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Operating Segment Information - Summary of Revenue from External Customers (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails", "shortName": "Operating Segment Information - Summary of Revenue from External Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_srtStatementGeographicalAxis_countryCN_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfNonCurrentAssetInformationTextBlock", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Operating Segment Information - Summary of Non-current Assets (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "shortName": "Operating Segment Information - Summary of Non-current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfNonCurrentAssetInformationTextBlock", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfVoluntaryChangeInAccountingPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Changes in Accounting Policies and Disclosures", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureChangesInAccountingPoliciesAndDisclosures", "shortName": "Changes in Accounting Policies and Disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfVoluntaryChangeInAccountingPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Operating Segment Information - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "shortName": "Operating Segment Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullCategoriesOfRelatedPartiesAxis_legnNanjingProbioBiotechCoLtdMember_20210101_20211231", "decimals": "-5", "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Revenue, Other Income and Gains - Summary of Analysis of Revenue (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "shortName": "Revenue, Other Income and Gains - Summary of Analysis of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProductsAndServicesAxis_legnLicensingOfIntellectualPropertyMember_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "legn:RevenueFromLicensingOfIntellectualProperty", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Revenue, Other Income and Gains - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "shortName": "Revenue, Other Income and Gains - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProductsAndServicesAxis_legnLicensingOfIntellectualPropertyMember_srtStatementGeographicalAxis_legnUSAndNonUSTerritoriesMember_20150527_20150527", "decimals": "-6", "lang": null, "name": "legn:RevenueFromLicensingOfIntellectualProperty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProductsAndServicesAxis_legnJointSteeringCommitteeServiceMember_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100920 - Disclosure - Revenue, Other Income and Gains - Summary of Revenue Recognized That Was Included in Contract Liabilities at Beginning of Reporting Period (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails", "shortName": "Revenue, Other Income and Gains - Summary of Revenue Recognized That Was Included in Contract Liabilities at Beginning of Reporting Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullProductsAndServicesAxis_legnJointSteeringCommitteeServiceMember_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Revenue, Other Income and Gains - Summary of Revenue Recognized From Performance Obligation Satisfied in Previous Periods (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "shortName": "Revenue, Other Income and Gains - Summary of Revenue Recognized From Performance Obligation Satisfied in Previous Periods (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory", "legn:DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Revenue, Other Income and Gains - Summary of Amounts of Transaction Prices Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails", "shortName": "Revenue, Other Income and Gains - Summary of Amounts of Transaction Prices Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinanceIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Revenue, Other Income and Gains - Other Income and Gains (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails", "shortName": "Revenue, Other Income and Gains - Other Income and Gains (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "ix:continuation", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinanceIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Loss Before Tax - Summery of loss before tax is arrived at after charging/(crediting) (Detail)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail", "shortName": "Loss Before Tax - Summery of loss before tax is arrived at after charging/(crediting) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "legn:DisclosureOfProfitLossBeforeTaxArrivedAfterChargingAndCreditingExplanatory", "legn:ProfitLossBeforeTaxExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_legnProfitLossBeforeTaxArrivedAfterChargingAndCreditingMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Finance Costs - Summary of Finance Costs (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails", "shortName": "Finance Costs - Summary of Finance Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinanceCostExplanatory", "legn:EntireDisclosureOfFinanceCostsExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_20200101_20201231", "decimals": "-3", "lang": null, "name": "legn:ExpensesForIssuanceOfConvertibleRedeemablePreferredShares", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullGeographicalAreasAxis_countryHK_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217HKD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Income Tax - Additional Information (Details)", "role": "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "shortName": "Income Tax - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "legn-20f_20211231.htm", "contextRef": "C_0001801198_ifrs-fullGeographicalAreasAxis_countryHK_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217HKD", "xsiNil": "false" } } }, "segmentCount": 135, "tag": { "country_BE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BELGIUM", "terseLabel": "Belgium" } } }, "localname": "BE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States of America", "verboseLabel": "United States of America" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "C N Y", "terseLabel": "Denominated in RMB" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "E U R", "terseLabel": "Denominated in EUR" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U S D", "terseLabel": "Denominated in USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings Exchange [Axis]", "terseLabel": "Entity Listings, Exchange" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r57", "r58" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Accounting Profit", "terseLabel": "Taxable income" } } }, "localname": "AccountingProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r67", "r75", "r126", "r137", "r140" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated Depreciation And Amortisation [Member]", "terseLabel": "Accumulated Depreciation", "verboseLabel": "Accumulated Amortization" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r127" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions Other Than Through Business Combinations Property Plant And Equipment", "terseLabel": "Additions", "verboseLabel": "Additions of property, plant and equipment" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions To Rightofuse Assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AddressOfRegisteredOfficeOfEntity": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "The address at which the entity's office is registered." } }, "en-us": { "role": { "label": "Address Of Registered Office Of Entity", "terseLabel": "Address of entity's registered office" } } }, "localname": "AddressOfRegisteredOfficeOfEntity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10520.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments For Amortisation Expense", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "auth_ref": [ "r55" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10170.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods." } }, "en-us": { "role": { "label": "Adjustments For Current Tax Of Prior Period", "terseLabel": "Prior year true up" } } }, "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r150" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10390.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Decrease Increase In Inventories", "terseLabel": "Decrease/(increase) in inventories" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10380.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Decrease Increase In Other Current Assets", "terseLabel": "Increase in other non-current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "auth_ref": [ "r150" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10360.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Decrease Increase In Trade Account Receivable", "terseLabel": "Decrease/(increase) in trade receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationExpense": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10500.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Depreciation Expense", "terseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "AdjustmentsForDepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r151" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10560.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Fair Value Gains Losses", "terseLabel": "Fair value gains on financial assets measured at fair value change through profit or loss" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r152" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10480.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Finance Costs", "terseLabel": "Finance costs" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10470.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Finance Income", "negatedLabel": "Finance income" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10490.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on trade and other receivables recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]" } }, "en-us": { "role": { "label": "Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss Trade And Other Receivables", "terseLabel": "(Reversal of)/provision for the impairment of trade receivables" } } }, "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "auth_ref": [ "r150" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10420.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Increase Decrease In Other Operating Payables", "terseLabel": "Increase in other payables and accruals" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r153" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10410.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Increase Decrease In Trade And Other Payables", "terseLabel": "Increase/(decrease) in trade and notes payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments For Reconcile Profit Loss [Abstract]", "terseLabel": "Adjustments for:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r151", "r166" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10570.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments For Unrealised Foreign Exchange Losses Gains", "terseLabel": "Foreign currency exchange loss/(gain), net" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdministrativeExpense": { "auth_ref": [ "r2", "r52", "r107" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10100.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } }, "en-us": { "role": { "label": "Administrative Expense", "negatedLabel": "Administrative expenses" } } }, "localname": "AdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r135", "r139", "r189" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated Measurement [Member]", "terseLabel": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r26", "r79", "r205", "r216", "r217", "r241", "r263", "r265", "r286", "r287", "r289", "r295" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated Time Bands [Member]", "terseLabel": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r78", "r190" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All Levels Of Fair Value Hierarchy [Member]", "terseLabel": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllowanceAccountForCreditLossesOfFinancialAssets": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an allowance account used to record impairments to financial assets due to credit losses. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Allowance Account For Credit Losses Of Financial Assets", "negatedLabel": "Less: Impairment of trade receivables", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Expected credit loss" } } }, "localname": "AllowanceAccountForCreditLossesOfFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfMovementsInLossAllowanceForImpairmentOfTradeReceivablesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation Intangible Assets Other Than Goodwill", "negatedLabel": "Amortization provided during the year" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmortisationMethodIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r125" ], "lang": { "en": { "role": { "documentation": "The amortisation method used for intangible assets other than goodwill with finite useful lives. [Refer: Intangible assets other than goodwill; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Amortisation Method Intangible Assets Other Than Goodwill", "terseLabel": "Useful economic lives of intangible assets" } } }, "localname": "AmortisationMethodIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r95", "r99" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts Payable Related Party Transactions", "terseLabel": "Due to related parties" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "auth_ref": [ "r95", "r99" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts Receivable Related Party Transactions", "positiveLabel": "Trade receivables due from related parties", "terseLabel": "Other receivables due from related parties" } } }, "localname": "AmountsReceivableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable Tax Rate", "terseLabel": "Income tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r23", "r189", "r190", "r193", "r274", "r277" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average Effective Tax Rate", "totalLabel": "Tax charge/(benefit) at the Group\u2019s effective rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r115", "r116" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic Earnings Loss Per Share", "terseLabel": "Basic" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "perShareItemType" }, "ifrs-full_BasicEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic Earnings Per Share [Abstract]" } } }, "localname": "BasicEarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "terseLabel": "Funding advances from collaborator principal amount" } } }, "localname": "Borrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings Adjustment To Interest Rate Basis", "terseLabel": "Borrowings, adjustment to interest rate basis" } } }, "localname": "BorrowingsAdjustmentToInterestRateBasis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings By Name [Axis]", "terseLabel": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings By Name [Member]", "terseLabel": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings Interest Rate", "terseLabel": "Effective interest rate (%)", "verboseLabel": "Borrowings, interest rate" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BorrowingsInterestRateBasis": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings Interest Rate Basis", "terseLabel": "Borrowings, interest rate basis" } } }, "localname": "BorrowingsInterestRateBasis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsMaturity": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The maturity of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings Maturity", "terseLabel": "Maturity" } } }, "localname": "BorrowingsMaturity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r195", "r196", "r197", "r230", "r259", "r289" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom Of Range [Member]", "terseLabel": "Bottom Of Range [Member]", "verboseLabel": "Bottom of Range" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BuildingsMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Buildings [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Commitments [Abstract]" } } }, "localname": "CapitalCommitmentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CapitalRequirementsAxis": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Capital Requirements [Axis]", "terseLabel": "Capital requirements [axis]" } } }, "localname": "CapitalRequirementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_CapitalRequirementsMember": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "This member stands for capital requirements that the entity is subject to. It also represents the standard value for the 'Capital requirements' axis if no other member is used." } }, "en-us": { "role": { "label": "Capital Requirements [Member]", "terseLabel": "Capital requirements [member]" } } }, "localname": "CapitalRequirementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r67", "r72", "r126", "r130", "r136", "r137", "r138", "r139", "r140", "r237", "r248", "r249", "r303", "r308" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount [Axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r72", "r130", "r136", "r138", "r139", "r237", "r248", "r249", "r303", "r307" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying Amount [Member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash and bank balances" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAdvancesAndLoansFromRelatedParties": { "auth_ref": [ "r148" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10040.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Cash Advances And Loans From Related Parties", "terseLabel": "Proceeds from cash advances from related parties" } } }, "localname": "CashAdvancesAndLoansFromRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": { "auth_ref": [ "r144" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10210.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Cash Advances And Loans Made To Related Parties", "negatedLabel": "Cash advances to related parties", "terseLabel": "Cash advances to related parties" } } }, "localname": "CashAdvancesAndLoansMadeToRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndBankBalancesAtCentralBanks": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash and bank balances held at central banks." } }, "en-us": { "role": { "label": "Cash And Bank Balances At Central Banks", "terseLabel": "Cash and bank balances" } } }, "localname": "CashAndBankBalancesAtCentralBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r20", "r163", "r186" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10260.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash And Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF YEAR", "periodStartLabel": "Cash and cash equivalents at beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents [Abstract]", "terseLabel": "ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r141", "r165" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10030.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities", "totalLabel": "Net cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r141", "r165" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10020.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities", "totalLabel": "Net cash flows used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r141", "r165" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10010.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities", "totalLabel": "Net cash flow used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r153", "r166" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10290.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash Flows From Used In Operations", "totalLabel": "Cash used in operations" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "auth_ref": [ "r153", "r166" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10350.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } }, "en-us": { "role": { "label": "Cash Flows From Used In Operations Before Changes In Working Capital", "totalLabel": "Cash flows from (used in) operations before changes in working capital" } } }, "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r212" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash Outflow For Leases", "negatedLabel": "Payments", "totalLabel": "Cash outflow for leases" } } }, "localname": "CashOutflowForLeases", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties": { "auth_ref": [ "r144" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10220.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from repayment to the entity of loans and advances made to related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Cash Receipts From Repayment Of Advances And Loans Made To Related Parties", "terseLabel": "Collection of cash advances to related parties" } } }, "localname": "CashReceiptsFromRepaymentOfAdvancesAndLoansMadeToRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": { "auth_ref": [ "r148" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10050.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for repayments of advances and loans from related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Cash Repayments Of Advances And Loans From Related Parties", "negatedLabel": "Repayment of cash advances from related parties", "terseLabel": "Repayment of cash advances from related parties" } } }, "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfCurrentFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Categories Of Current Financial Assets [Abstract]" } } }, "localname": "CategoriesOfCurrentFinancialAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Categories Of Financial Assets [Abstract]" } } }, "localname": "CategoriesOfFinancialAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Related Parties [Axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r120", "r123", "r194", "r215" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Assets [Axis]", "terseLabel": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r120", "r194", "r215" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Classes Of Assets [Member]", "terseLabel": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r257", "r258", "r284", "r297", "r298", "r299" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Assets [Axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r248", "r250", "r252", "r254" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Axis]", "terseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r248", "r250", "r252", "r254" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Classes Of Financial Instruments [Member]", "terseLabel": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Intangible Assets Other Than Goodwill [Axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Classes Of Inventories [Abstract]" } } }, "localname": "ClassesOfInventoriesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Property Plant And Equipment [Axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Share Capital [Axis]", "terseLabel": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Classes Of Share Capital [Member]", "terseLabel": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components Of Equity [Axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax [Abstract]", "terseLabel": "Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r3", "r42", "r172", "r174", "r178", "r183" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10010.0, "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive Income", "totalLabel": "TOTAL COMPREHENSIVE LOSS FOR THE YEAR" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Attributable To [Abstract]", "terseLabel": "Attributable to:" } } }, "localname": "ComprehensiveIncomeAttributableToAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r3", "r44" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive Income Attributable To Owners Of Parent", "totalLabel": "Ordinary equity holders of the parent" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer Software [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r198", "r201" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract Liabilities", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesSummaryOfMovementsInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract Liabilities [Abstract]" } } }, "localname": "ContractLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CountryOfIncorporation": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "The country in which the entity is incorporated." } }, "en-us": { "role": { "label": "Country Of Incorporation", "terseLabel": "Country of incorporation" } } }, "localname": "CountryOfIncorporation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r270", "r290", "r291", "r292", "r293" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency Risk [Member]", "terseLabel": "Foreign Currency Risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "auth_ref": [ "r56" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate current and deferred tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Deferred tax relating to items credited (charged) directly to equity; Retained earnings; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Current And Deferred Tax Relating To Items Charged Or Credited Directly To Equity", "totalLabel": "Total tax charge/(credit) for the year" } } }, "localname": "CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r27", "r178", "r179" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10190.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current Assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r198" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails": { "order": 10010.0, "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10170.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current Contract Liabilities", "positiveVerboseLabel": "Current", "terseLabel": "Contract liabilities" } } }, "localname": "CurrentContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10160.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Current Derivative Financial Liabilities", "terseLabel": "Warrant liability" } } }, "localname": "CurrentDerivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentGovernmentGrants": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails": { "order": 10010.0, "parentTag": "ifrs-full_GovernmentGrants", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10140.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Current Government Grants", "terseLabel": "Government grants", "verboseLabel": "Current" } } }, "localname": "CurrentGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r208" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10150.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Current portion" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r29", "r178", "r181" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10050.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current Liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10220.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current Prepayments And Other Current Assets", "terseLabel": "Prepayments, other receivables and other assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]" } }, "en-us": { "role": { "label": "Current Raw Materials And Current Production Supplies", "totalLabel": "Raw materials and consumables" } } }, "localname": "CurrentRawMaterialsAndCurrentProductionSupplies", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "auth_ref": [ "r56" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails": { "order": 10010.0, "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Retained earnings; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Current Tax Relating To Items Charged Or Credited Directly To Equity", "terseLabel": "Current - Tax charge" } } }, "localname": "CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r28", "r31" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10210.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current Trade Receivables", "terseLabel": "Trade receivables, net", "verboseLabel": "Gross carrying amount" } } }, "localname": "CurrentTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": { "auth_ref": [ "r221", "r236" ], "lang": { "en": { "role": { "documentation": "The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Date Of Grant Of Sharebased Payment Arrangement", "terseLabel": "Effective date of share option scheme" } } }, "localname": "DateOfGrantOfSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "auth_ref": [ "r59" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails": { "order": 10010.0, "parentTag": "legn_DeferredTaxAssetNotYetRecognized", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deductible Temporary Differences For Which No Deferred Tax Asset Is Recognised", "terseLabel": "Deductible temporary differences" } } }, "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets And Liabilities [Abstract]" } } }, "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxExpenseIncome": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred Tax Expense Income", "terseLabel": "Tax losses" } } }, "localname": "DeferredTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "auth_ref": [ "r56" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails": { "order": 10030.0, "parentTag": "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred Tax Relating To Items Charged Or Credited Directly To Equity", "terseLabel": "Deferred" } } }, "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r70", "r74" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation Property Plant And Equipment", "negatedLabel": "Depreciation provided during the year" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRatePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation Rate Property Plant And Equipment", "terseLabel": "Estimated useful lives of property, plant and equipment" } } }, "localname": "DepreciationRatePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r209" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation Rightofuse Assets", "negatedLabel": "Depreciation of right-of-use assets", "terseLabel": "Depreciation charge of right-of-use assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Employee Benefits Explanatory", "terseLabel": "Other employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Fair Value Measurement Explanatory", "terseLabel": "Fair value measurement" } } }, "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Financial Instruments At Fair Value Through Profit Or Loss Explanatory", "terseLabel": "Financial assets at fair value through profit or loss" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Financial Liabilities Explanatory", "terseLabel": "Financial liabilities" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Foreign Currency Translation Explanatory", "terseLabel": "Foreign currencies" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "auth_ref": [ "r86" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Government Grants", "terseLabel": "Government grants" } } }, "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Impairment Of Financial Assets Explanatory", "terseLabel": "Impairment of financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Impairment Of Nonfinancial Assets Explanatory", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Income Tax Explanatory", "terseLabel": "Income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Leases Explanatory", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Measuring Inventories", "terseLabel": "Inventories" } } }, "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Property Plant And Equipment Explanatory", "terseLabel": "Property, plant and equipment and depreciation" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Recognition Of Revenue", "terseLabel": "Revenue recognition" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Research And Development Expense Explanatory", "terseLabel": "Research and development costs" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Sharebased Payment Transactions Explanatory", "terseLabel": "Share-based payments" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions with related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy For Transactions With Related Parties Explanatory", "terseLabel": "Related parties" } } }, "localname": "DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description Of Accounting Policy To Determine Components Of Cash And Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "auth_ref": [ "r170" ], "lang": { "en": { "role": { "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have." } }, "en-us": { "role": { "label": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations", "terseLabel": "Issued But Not Yet Effective International Financial Reporting Standards" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIssuedButNotYetEffectiveInternationalFinancialReportingStandards" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Abstract]" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]", "terseLabel": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": { "auth_ref": [ "r170" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations." } }, "en-us": { "role": { "label": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table]", "terseLabel": "Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table]" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Description Of Expected Volatility Share Options Granted", "terseLabel": "Expected volatility (%)" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": { "auth_ref": [ "r15" ], "lang": { "en": { "role": { "documentation": "The description of the nature of the entity's operations and principal activities." } }, "en-us": { "role": { "label": "Description Of Nature Of Entitys Operations And Principal Activities", "terseLabel": "Principal activities" } } }, "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfNatureOfRelatedPartyRelationship": { "auth_ref": [ "r96" ], "lang": { "en": { "role": { "documentation": "The description of the nature of the related party relationships. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Description Of Nature Of Related Party Relationship", "terseLabel": "Relationship" } } }, "localname": "DescriptionOfNatureOfRelatedPartyRelationship", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Description Of Option Life Share Options Granted", "terseLabel": "Expected life of options (year)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Description Of Risk Free Interest Rate Share Options Granted", "terseLabel": "Risk-free interest rate (%)" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description Of Useful Life Property Plant And Equipment", "terseLabel": "Estimated useful lives of property, plant and equipment" } } }, "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfVoluntaryChangeInAccountingPolicy": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The disclosure of a voluntary change in accounting policy." } }, "en-us": { "role": { "label": "Description Of Voluntary Change In Accounting Policy", "terseLabel": "Changes in Accounting Policies and Disclosures" } } }, "localname": "DescriptionOfVoluntaryChangeInAccountingPolicy", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureChangesInAccountingPoliciesAndDisclosures" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r115", "r116" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted Earnings Loss Per Share", "terseLabel": "Diluted" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Accounting Judgements And Estimates Explanatory", "terseLabel": "Significant Accounting Judgements and Estimates" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimates" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the allowance relating to impairments of financial assets due to credit losses. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Disclosure Of Allowance For Credit Losses Explanatory", "terseLabel": "Summary of Movements in Loss Allowance for Impairment of Trade Receivables" } } }, "localname": "DisclosureOfAllowanceForCreditLossesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the authorisation of financial statements for issue." } }, "en-us": { "role": { "label": "Disclosure Of Authorisation Of Financial Statements Explanatory", "terseLabel": "Approval of the Consolidated Financial Statements" } } }, "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureApprovalOfConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure Of Borrowings Explanatory", "terseLabel": "Interest-Bearing Loans and Borrowings" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowings" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure Of Cash And Cash Equivalents Explanatory", "terseLabel": "Cash and Cash Equivalents, Time Deposits and Pledged Deposits" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDeposits" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r168" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure Of Cash Flow Statement Explanatory", "terseLabel": "Notes to the Consolidated Statement of Cash Flows" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlows" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital Explanatory", "terseLabel": "Share Capital and Share Premium" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremium" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Line Items]", "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure Of Classes Of Share Capital [Table]", "terseLabel": "Disclosure Of Classes Of Share Capital [Table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure Of Commitments Explanatory", "terseLabel": "Commitments and Contingencies" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Disclosure Of Deferred Taxes Explanatory", "terseLabel": "Deferred Tax" } } }, "localname": "DisclosureOfDeferredTaxesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Disclosure Of Depreciation And Amortisation Expense Explanatory", "terseLabel": "Summary of Depreciation Calculated on Straight-line Basis Over Estimated Useful Lives of Assets" } } }, "localname": "DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Detailed Information About Borrowings [Abstract]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Borrowings Explanatory", "terseLabel": "Summary of Interest-Bearing Loans and Borrowings" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Borrowings [Line Items]", "terseLabel": "Disclosure Of Detailed Information About Borrowings [Line Items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Borrowings [Table]", "terseLabel": "Disclosure Of Detailed Information About Borrowings [Table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r243", "r250", "r259" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Financial Instruments Explanatory", "terseLabel": "Financial Instruments by Category" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategory" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Intangible Assets Explanatory", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure Of Detailed Information About Property Plant And Equipment Explanatory", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Abstract]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers Explanatory", "terseLabel": "Summary of Analysis of Revenue" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]", "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]", "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure Of Earnings Per Share Explanatory", "terseLabel": "Loss per Share Attributable to Ordinary Equity Holders of the Parent" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParent" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "auth_ref": [ "r194" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } }, "en-us": { "role": { "label": "Disclosure Of Fair Value Measurement Of Liabilities Explanatory", "terseLabel": "Summary of Fair Value Measurement Hierarchy of Financial Instruments" } } }, "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Fair Value Of Financial Instruments Explanatory", "terseLabel": "Fair Value and Fair Value Hierarchy of Financial Instruments" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance cost. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Disclosure Of Finance Cost Explanatory", "terseLabel": "Summary of Finance Costs" } } }, "localname": "DisclosureOfFinanceCostExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Financial Assets [Abstract]" } } }, "localname": "DisclosureOfFinancialAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets Explanatory", "terseLabel": "Summary of Financial Assets" } } }, "localname": "DisclosureOfFinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Line Items]", "terseLabel": "Disclosure Of Financial Assets [Line Items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure Of Financial Assets [Table]", "terseLabel": "Disclosure Of Financial Assets [Table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r271" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments Explanatory", "terseLabel": "Financial Risk Management Objectives and Policies" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Line Items]", "terseLabel": "Disclosure Of Financial Instruments [Line Items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r243", "r250", "r259" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure Of Financial Instruments [Table]", "terseLabel": "Disclosure Of Financial Instruments [Table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Financial Liabilities [Abstract]" } } }, "localname": "DisclosureOfFinancialLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure Of Financial Liabilities Explanatory", "terseLabel": "Summary of Financial Liabilities" } } }, "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategoryTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Financial Liabilities [Line Items]", "terseLabel": "Disclosure Of Financial Liabilities [Line Items]" } } }, "localname": "DisclosureOfFinancialLiabilitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "auth_ref": [ "r259" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } }, "en-us": { "role": { "label": "Disclosure Of Financial Liabilities [Table]", "terseLabel": "Disclosure Of Financial Liabilities [Table]" } } }, "localname": "DisclosureOfFinancialLiabilitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "auth_ref": [ "r282" ], "lang": { "en": { "role": { "documentation": "The disclosure of geographical information." } }, "en-us": { "role": { "label": "Disclosure Of Geographical Areas Explanatory", "terseLabel": "Summary of Revenue from External Customers" } } }, "localname": "DisclosureOfGeographicalAreasExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "auth_ref": [ "r88" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for government grants." } }, "en-us": { "role": { "label": "Disclosure Of Government Grants Explanatory", "terseLabel": "Government Grants" } } }, "localname": "DisclosureOfGovernmentGrantsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrants" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure Of Income Tax Explanatory", "terseLabel": "Income Tax" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r233" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period Explanatory", "terseLabel": "Summary of Fair Value of Equity Settled Share Options Granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Intangible Assets [Abstract]" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure Of Intangible Assets Explanatory", "terseLabel": "Intangible Assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Intangible Assets [Line Items]", "terseLabel": "Disclosure Of Intangible Assets [Line Items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure Of Intangible Assets [Table]", "terseLabel": "Disclosure Of Intangible Assets [Table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for inventories." } }, "en-us": { "role": { "label": "Disclosure Of Inventories Explanatory", "terseLabel": "Inventories" } } }, "localname": "DisclosureOfInventoriesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r218", "r219" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure Of Leases Explanatory", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisForFinancialAssetsHeldForManagingLiquidityRiskExplanatory": { "auth_ref": [ "r264" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis for financial assets held for managing liquidity risk. [Refer: Financial assets; Liquidity risk [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Maturity Analysis For Financial Assets Held For Managing Liquidity Risk Explanatory", "terseLabel": "Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments" } } }, "localname": "DisclosureOfMaturityAnalysisForFinancialAssetsHeldForManagingLiquidityRiskExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Maturity Analysis Of Operating Lease Payments [Abstract]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r217" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Disclosure Of Maturity Analysis Of Operating Lease Payments Explanatory", "terseLabel": "Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Operating Leases" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Maturity Analysis Of Operating Lease Payments [Line Items]", "terseLabel": "Disclosure Of Maturity Analysis Of Operating Lease Payments [Line Items]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "auth_ref": [ "r217" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } }, "en-us": { "role": { "label": "Disclosure Of Maturity Analysis Of Operating Lease Payments [Table]", "terseLabel": "Disclosure Of Maturity Analysis Of Operating Lease Payments [Table]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } }, "en-us": { "role": { "label": "Disclosure Of Notes And Other Explanatory Information Explanatory", "terseLabel": "Corporate Information" } } }, "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments Explanatory", "terseLabel": "Summary of Movement in Number of RSU Outstanding" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r228" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Share Options Explanatory", "terseLabel": "Summary of Share Options Outstanding Under the Scheme" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Abstract]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]", "terseLabel": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "auth_ref": [ "r230" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } }, "en-us": { "role": { "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Table]", "terseLabel": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Table]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Operating Segments [Abstract]" } } }, "localname": "DisclosureOfOperatingSegmentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "auth_ref": [ "r274" ], "lang": { "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Operating Segments Explanatory", "terseLabel": "Operating Segment Information" } } }, "localname": "DisclosureOfOperatingSegmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Operating Segments [Line Items]", "terseLabel": "Disclosure Of Operating Segments [Line Items]" } } }, "localname": "DisclosureOfOperatingSegmentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "auth_ref": [ "r274" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } }, "en-us": { "role": { "label": "Disclosure Of Operating Segments [Table]", "terseLabel": "Disclosure Of Operating Segments [Table]" } } }, "localname": "DisclosureOfOperatingSegmentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } }, "en-us": { "role": { "label": "Disclosure Of Other Noncurrent Assets Explanatory", "terseLabel": "Other Non-Current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Disclosure Of Other Operating Income Explanatory", "terseLabel": "Other Income and Gains" } } }, "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment Explanatory", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Line Items]", "terseLabel": "Disclosure Of Property Plant And Equipment [Line Items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure Of Property Plant And Equipment [Table]", "terseLabel": "Disclosure Of Property Plant And Equipment [Table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfProvisionMatrixExplanatory": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "The disclosure of the provision matrix." } }, "en-us": { "role": { "label": "Disclosure Of Provision Matrix Explanatory", "terseLabel": "Summary of Information About Credit Risk Exposure on Group's Trade Receivables Using Provision Matrix" } } }, "localname": "DisclosureOfProvisionMatrixExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfProvisionMatrixLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Provision Matrix [Line Items]", "terseLabel": "Disclosure Of Provision Matrix [Line Items]" } } }, "localname": "DisclosureOfProvisionMatrixLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfProvisionMatrixTable": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the provision matrix." } }, "en-us": { "role": { "label": "Disclosure Of Provision Matrix [Table]", "terseLabel": "Disclosure Of Provision Matrix [Table]" } } }, "localname": "DisclosureOfProvisionMatrixTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Abstract]", "terseLabel": "Right-of-use assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets Explanatory", "terseLabel": "Summary of Carrying Amounts of The Right-of-use Assets and Movements" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]", "terseLabel": "Disclosure Of Quantitative Information About Rightofuse Assets [Table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "auth_ref": [ "r230" ], "lang": { "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } }, "en-us": { "role": { "label": "Disclosure Of Range Of Exercise Prices Of Outstanding Share Options Explanatory", "terseLabel": "Summary of Exercise Prices and Exercise Periods of Share Options Outstanding" } } }, "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Abstract]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities Explanatory", "terseLabel": "Summary of Changes in Liabilities Arising from Financing Activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]", "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } }, "en-us": { "role": { "label": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]", "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r105" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure Of Related Party Explanatory", "terseLabel": "Related Party Transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Reserves And Other Equity Interest Explanatory", "terseLabel": "Reserves" } } }, "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureReserves" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReservesWithinEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Reserves Within Equity [Abstract]" } } }, "localname": "DisclosureOfReservesWithinEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory", "terseLabel": "Summary of Shares" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r220" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Sharebased Payment Arrangements Explanatory", "terseLabel": "Share Option Scheme" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionScheme" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Significant Investments In Subsidiaries [Abstract]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "auth_ref": [ "r111", "r114", "r188" ], "lang": { "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Significant Investments In Subsidiaries Explanatory", "terseLabel": "Information About Subsidiaries" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Significant Investments In Subsidiaries [Line Items]", "terseLabel": "Disclosure Of Significant Investments In Subsidiaries [Line Items]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "auth_ref": [ "r111", "r114", "r188" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } }, "en-us": { "role": { "label": "Disclosure Of Significant Investments In Subsidiaries [Table]", "terseLabel": "Disclosure Of Significant Investments In Subsidiaries [Table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure Of Summary Of Significant Accounting Policies Explanatory", "terseLabel": "Summary Of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]", "terseLabel": "Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure Of Trade And Other Payables Explanatory", "terseLabel": "Trade and Notes Payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Disclosure Of Trade And Other Receivables Explanatory", "terseLabel": "Trade Receivables" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Abstract]" } } }, "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": { "auth_ref": [ "r205" ], "lang": { "en": { "role": { "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers." } }, "en-us": { "role": { "label": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations Explanatory", "terseLabel": "Summary of Amounts of Transaction Prices Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)" } } }, "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]", "terseLabel": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]" } } }, "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable": { "auth_ref": [ "r205" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the transaction price allocated to the remaining performance obligations in contracts with customers." } }, "en-us": { "role": { "label": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Table]", "terseLabel": "Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Table]" } } }, "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r96" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties Explanatory", "terseLabel": "Summary of Transactions with Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Line Items]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Line Items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure Of Transactions Between Related Parties [Table]", "terseLabel": "Disclosure Of Transactions Between Related Parties [Table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Voluntary Change In Accounting Policy [Abstract]" } } }, "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals Property Plant And Equipment", "negatedLabel": "Disposals" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r115" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings Per Share Explanatory", "terseLabel": "Summary of Calculations of Basic and Diluted Loss per Share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r154", "r155" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect Of Exchange Rate Changes On Cash And Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes, net" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForProbabilityOfDefaultMember": { "auth_ref": [ "r252", "r266" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Probability of default' axis if no other member is used." } }, "en-us": { "role": { "label": "Entitys Total For Probability Of Default [Member]", "terseLabel": "Entity's total for probability of default [member]" } } }, "localname": "EntitysTotalForProbabilityOfDefaultMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entitys Total For Related Parties [Member]", "terseLabel": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r111", "r114", "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entitys Total For Subsidiaries [Member]", "terseLabel": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r23", "r32", "r171", "r173", "r189", "r190", "r193" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10020.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity And Liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r22" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity Attributable To Owners Of Parent", "totalLabel": "Total ordinary shareholders\u2019 equity" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [Member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityPriceRiskMember": { "auth_ref": [ "r255", "r269" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of other price risk that represents the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in equity prices. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Equity Price Risk [Member]", "terseLabel": "Capital Management" } } }, "localname": "EquityPriceRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ExchangeDifferencesOnTranslationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange Differences On Translation [Abstract]", "terseLabel": "Exchange differences:" } } }, "localname": "ExchangeDifferencesOnTranslationAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [ "r230" ], "lang": { "en": { "role": { "documentation": "The exercise price of outstanding share options." } }, "en-us": { "role": { "label": "Exercise Price Of Outstanding Share Options2019", "terseLabel": "Exercise price per share" } } }, "localname": "ExercisePriceOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise Price Share Options Granted2019", "terseLabel": "Underlying stock price" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpectedCreditLossRate": { "auth_ref": [ "r253", "r267" ], "lang": { "en": { "role": { "documentation": "The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights." } }, "en-us": { "role": { "label": "Expected Credit Loss Rate", "terseLabel": "Expected loss rate" } } }, "localname": "ExpectedCreditLossRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected Dividend As Percentage Share Options Granted", "terseLabel": "Dividend yield (%)" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense From Equitysettled Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets", "terseLabel": "Equity-settled share option expense" } } }, "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10580.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense From Sharebased Payment Transactions With Employees", "terseLabel": "Equity-settled share-based compensation expense", "verboseLabel": "Equity-settled share-based compensation expense" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } }, "en-us": { "role": { "label": "Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used", "terseLabel": "Expense relating to short-term leases" } } }, "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfUnfulfilledConditionsAndOtherContingenciesAttachingToGovernmentAssistance": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The explanation of unfulfilled conditions and other contingencies attaching to government assistance that has been recognised. [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Explanation Of Unfulfilled Conditions And Other Contingencies Attaching To Government Assistance", "terseLabel": "Explanation of unfulfilled conditions and other contingencies attaching to government assistance" } } }, "localname": "ExplanationOfUnfulfilledConditionsAndOtherContingenciesAttachingToGovernmentAssistance", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r46" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10150.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Costs", "negatedLabel": "Finance costs", "totalLabel": "Total" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r49" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10060.0, "parentTag": "us-gaap_OtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance Income", "terseLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r156" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10310.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]" } }, "en-us": { "role": { "label": "Finance Income Received Classified As Operating Activities", "terseLabel": "Finance income received" } } }, "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCost": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets At Amortised Cost", "terseLabel": "Financial assets measured at amortized cost", "verboseLabel": "Financial assets at amortized cost" } } }, "localname": "FinancialAssetsAtAmortisedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r257", "r258", "r284", "r297", "r298", "r299" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial Assets [Member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r242" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial Liabilities", "totalLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "auth_ref": [ "r262", "r304" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Liabilities At Amortised Cost", "terseLabel": "Financial liabilities at amortized cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r260" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial Liabilities At Fair Value Through Profit Or Loss", "terseLabel": "Financial liabilities at fair value through profit and loss" } } }, "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10510.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Gains Losses On Disposals Of Property Plant And Equipment", "negatedLabel": "Loss on disposal of property, plant and equipment" } } }, "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r16", "r89" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss", "verboseLabel": "Decrease/ (increase) in loss before tax" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r239" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10040.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Gains Losses On Financial Assets At Fair Value Through Profit Or Loss", "terseLabel": "Fair value gains on financial assets measured at fair value change through profit or loss" } } }, "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r77", "r207", "r282", "r296" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical Areas [Axis]", "terseLabel": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r77", "r207", "r282", "r296" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical Areas [Member]", "terseLabel": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government Grants", "totalLabel": "Deferred government grants" } } }, "localname": "GovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r67", "r126", "r137", "r140", "r237", "r249", "r252", "r253", "r303", "r308" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross Carrying Amount [Member]", "terseLabel": "Cost", "verboseLabel": "Gross Carrying Amount" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r119", "r122" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]" } }, "en-us": { "role": { "label": "Impairment Loss Recognised In Profit Or Loss", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Trade receivables]" } }, "en-us": { "role": { "label": "Impairment Loss Recognised In Profit Or Loss Trade Receivables", "terseLabel": "Impairment losses recognized" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfMovementsInLossAllowanceForImpairmentOfTradeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r47", "r54", "r57", "r58", "r108", "r187", "r273" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10060.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Income Tax Expense Continuing Operations", "negatedLabel": "Income tax (expense)/credit", "totalLabel": "Tax charge/(benefit) at the Group\u2019s effective rate" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r157" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10300.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } }, "en-us": { "role": { "label": "Income Taxes Paid Classified As Operating Activities", "negatedLabel": "Income tax paid" } } }, "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "auth_ref": [ "r142", "r157" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10330.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income Taxes Paid Refund Classified As Operating Activities", "negatedLabel": "Income tax received" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r163" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes", "totalLabel": "NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase Decrease Through Conversion Of Convertible Instruments", "negatedLabel": "Conversion to ordinary shares", "terseLabel": "Conversion of convertible redeemable preferred shares to ordinary shares" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r159" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase Decrease Through Effect Of Changes In Foreign Exchange Rates Liabilities Arising From Financing Activities", "terseLabel": "Exchange realignment", "verboseLabel": "Foreign exchange movement" } } }, "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase Decrease Through Exercise Of Options", "terseLabel": "Exercise of share options" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r158" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities", "terseLabel": "Changes from financing cash flows" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase Decrease Through Net Exchange Differences Intangible Assets Other Than Goodwill", "terseLabel": "Exchange realignment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase Decrease Through Net Exchange Differences Property Plant And Equipment", "terseLabel": "Exchange realignment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase Decrease Through Sharebased Payment Transactions", "terseLabel": "Equity-settled share-based compensation expense" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersFromToInvestmentPropertyPropertyPlantAndEquipment": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from (to) investment property. [Refer: Property, plant and equipment; Investment property]" } }, "en-us": { "role": { "label": "Increase Decrease Through Transfers From To Investment Property Property Plant And Equipment", "terseLabel": "Transfers" } } }, "localname": "IncreaseDecreaseThroughTransfersFromToInvestmentPropertyPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r160", "r166" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase Through New Leases Liabilities Arising From Financing Activities", "verboseLabel": "Additions of lease liabilities" } } }, "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InformationAboutMajorCustomers": { "auth_ref": [ "r283" ], "lang": { "en": { "role": { "documentation": "Information about the entity's major customers and the extent of the entity's reliance on them." } }, "en-us": { "role": { "label": "Information About Major Customers", "terseLabel": "Customer information" } } }, "localname": "InformationAboutMajorCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r18", "r130" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10310.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible Assets Other Than Goodwill", "periodEndLabel": "Net carrying amount, ending balance", "periodStartLabel": "Net carrying amount, beginning balance", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r121", "r131", "r215" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible Assets Other Than Goodwill [Member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAmortisedOnStraightLineBasisOverUsefulEconomicLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpenseOnBorrowings": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails": { "order": 10020.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } }, "en-us": { "role": { "label": "Interest Expense On Borrowings", "terseLabel": "Interest on interest-bearing loans and borrowings (note 26)", "verboseLabel": "Interest expense on borrowings" } } }, "localname": "InterestExpenseOnBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails": { "order": 10040.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]" } }, "en-us": { "role": { "label": "Interest Expense On Debt Instruments Issued", "terseLabel": "Interest on an entrusted loan from a related party" } } }, "localname": "InterestExpenseOnDebtInstrumentsIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r210" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails": { "order": 10010.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest Expense On Lease Liabilities", "terseLabel": "Interest on lease liabilities" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpenseDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r156" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest Paid Classified As Operating Activities", "negatedLabel": "Interest paid classified as operating cash flows" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivable": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": 10010.0, "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } }, "en-us": { "role": { "label": "Interest Receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r19", "r28", "r83" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10200.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Inventories", "terseLabel": "Inventories" } } }, "localname": "Inventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue Of Equity", "terseLabel": "Issuance of ordinary shares" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r32" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10030.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued Capital", "terseLabel": "Share capital", "verboseLabel": "308,456,852 (2020: 266,010,256) ordinary shares of US$0.0001 each" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued Capital [Member]", "terseLabel": "Share Capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation", "totalLabel": "Total compensation paid to key management personnel" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r93" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails": { "order": 10020.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Sharebased Payment", "terseLabel": "Equity-settled share-based compensation expense" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r91" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails": { "order": 10010.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Shortterm Employee Benefits", "terseLabel": "Short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": { "auth_ref": [ "r92" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails": { "order": 10030.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key Management Personnel Compensation Termination Benefits", "terseLabel": "Termination payment" } } }, "localname": "KeyManagementPersonnelCompensationTerminationBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfCompensationOfKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LandMember": { "auth_ref": [ "r63" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "verboseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r10", "r216", "r217", "r263", "r268", "r295" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "Later Than One Year And Not Later Than Two Years [Member]", "terseLabel": "1 - 2 years" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearMember": { "auth_ref": [ "r25", "r302", "r306" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year." } }, "en-us": { "role": { "label": "Later Than One Year [Member]", "verboseLabel": "Over 1 years" } } }, "localname": "LaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "auth_ref": [ "r10", "r216", "r217", "r263", "r268", "r295" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } }, "en-us": { "role": { "label": "Later Than Three Years And Not Later Than Four Years [Member]", "terseLabel": "3 - 4 years" } } }, "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "auth_ref": [ "r10", "r216", "r217", "r263", "r268", "r295" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } }, "en-us": { "role": { "label": "Later Than Two Years And Not Later Than Three Years [Member]", "terseLabel": "2 - 3 years" } } }, "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r208" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": 10050.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease Liabilities", "periodEndLabel": "Carrying amount, lease liabilities", "periodStartLabel": "Carrying amount, lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Liabilities [Abstract]", "terseLabel": "Analyzed into:" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r161", "r167" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease Liabilities [Member]", "terseLabel": "Lease liabilities [member]" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r78", "r190" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level1 Of Fair Value Hierarchy [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1)" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r190" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level2 Of Fair Value Hierarchy [Member]", "terseLabel": "Significant Observable Inputs (Level 2)" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r190" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level3 Of Fair Value Hierarchy [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r78", "r190" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels Of Fair Value Hierarchy [Axis]", "terseLabel": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r23", "r189", "r190", "r193", "r274", "r278" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10010.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r162" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Axis]", "terseLabel": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Liabilities Arising From Financing Activities [Member]", "terseLabel": "Liabilities arising from financing activities [member]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LiquidityRiskMember": { "auth_ref": [ "r244", "r290", "r291", "r292" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Liquidity Risk [Member]", "terseLabel": "Liquidity Risk" } } }, "localname": "LiquidityRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10070.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Longterm Borrowings", "terseLabel": "Interest-bearing loans and borrowings" } } }, "localname": "LongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Losses On Disposals Of Property Plant And Equipment", "terseLabel": "Loss on disposal of property, plant and equipment" } } }, "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MachineryMember": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Machinery [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Components Of Tax Expense Income [Abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r26", "r79", "r205", "r216", "r217", "r241", "r256", "r263", "r286", "r287", "r289", "r295" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [Axis]", "terseLabel": "Maturity [axis]", "verboseLabel": "Less than 1 years" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r135", "r139", "r189" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [Axis]", "terseLabel": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NameOfSubsidiary": { "auth_ref": [ "r109", "r112", "r175", "r176" ], "lang": { "en": { "role": { "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Name Of Subsidiary", "terseLabel": "Company" } } }, "localname": "NameOfSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r16", "r89" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10030.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net Foreign Exchange Gain", "terseLabel": "Foreign currency exchange gain, net" } } }, "localname": "NetForeignExchangeGain", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r27", "r178", "r180" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10180.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Noncurrent Assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Assets [Abstract]", "terseLabel": "NON-CURRENT ASSETS" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets; Types of insurance contracts [member]]" } }, "en-us": { "role": { "label": "Noncurrent Assets Other Than Financial Instruments Deferred Tax Assets Postemployment Benefit Assets And Rights Arising Under Insurance Contracts", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentContractLiabilities": { "auth_ref": [ "r198" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails": { "order": 10020.0, "parentTag": "ifrs-full_ContractLiabilities", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10080.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Contract Liabilities", "positiveVerboseLabel": "Non-current", "terseLabel": "Contract liabilities" } } }, "localname": "NoncurrentContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentGovernmentGrants": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails": { "order": 10020.0, "parentTag": "ifrs-full_GovernmentGrants", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10100.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Noncurrent Government Grants", "terseLabel": "Government grants", "verboseLabel": "Non-current" } } }, "localname": "NoncurrentGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsSummaryOfDeferredGovernmentGrantsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r208" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10090.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Lease Liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "Non-current portion" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r29", "r178", "r182" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10060.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Noncurrent Liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent Liabilities [Abstract]", "terseLabel": "NON-CURRENT LIABILITIES" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } }, "en-us": { "role": { "label": "Noncurrent Portion Of Noncurrent Loans Received", "terseLabel": "Loans from a collaborator" } } }, "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r24", "r216", "r217", "r263", "r268", "r295" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not Later Than One Year [Member]", "terseLabel": "Within 1 year", "verboseLabel": "Less than 1 years" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotLaterThanThreeMonthsMember": { "auth_ref": [ "r10", "r302", "r305" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } }, "en-us": { "role": { "label": "Not Later Than Three Months [Member]", "terseLabel": "Within 3 Months" } } }, "localname": "NotLaterThanThreeMonthsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfInformationAboutCreditRiskExposureOnGroupSTradeReceivablesUsingProvisionMatrixDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r231", "r234" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Instruments Other Equity Instruments Granted", "terseLabel": "Number of RSU, Granted during the year" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Other Equity Instruments Exercised Or Vested In Sharebased Payment Arrangement", "negatedLabel": "Number of RSU, Vested during the year" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Other Equity Instruments Forfeited In Sharebased Payment Arrangement", "negatedLabel": "Number of RSU, Forfeited during the year" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Other Equity Instruments Outstanding In Sharebased Payment Arrangement", "periodEndLabel": "Number of RSU, Outstanding at December 31", "periodStartLabel": "Number of RSU, Outstanding at January 1", "verboseLabel": "Number of RSU, outstanding" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r222", "r226", "r230" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Outstanding Share Options", "periodEndLabel": "At December 31, Number of options", "periodStartLabel": "At January 1,Number of options", "positiveLabel": "Number of share options outstanding", "terseLabel": "Number of options" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Exercisable In Sharebased Payment Arrangement", "terseLabel": "Exercisable at December 31, Number of options" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Exercised In Sharebased Payment Arrangement", "negatedLabel": "Exercised during the year, Number of options" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r224" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Forfeited In Sharebased Payment Arrangement", "negatedLabel": "Forfeited during the year, Number of options" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r223" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Granted In Sharebased Payment Arrangement", "terseLabel": "Granted during the year, Number of options" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number Of Shares Authorised", "terseLabel": "Number of shares authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number Of Shares Issued", "terseLabel": "Number of shares issued", "verboseLabel": "Ordinary shares, purchased" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued [Abstract]", "terseLabel": "Issued and fully paid:" } } }, "localname": "NumberOfSharesIssuedAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Number Of Shares Issued And Fully Paid", "terseLabel": "Number of shares issued and fully paid" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r37", "r115" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary Shares [Member]", "terseLabel": "Ordinary Shares", "verboseLabel": "Ordinary Shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r5", "r41", "r50", "r185" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other Comprehensive Income", "totalLabel": "OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income [Abstract]", "terseLabel": "OTHER COMPREHENSIVE INCOME/(LOSS)", "verboseLabel": "Other comprehensive income/ loss:" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r30", "r50" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 10020.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10030.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Differences On Translation", "terseLabel": "Exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r48", "r53" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10020.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax", "totalLabel": "Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods" } } }, "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r1", "r52" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10120.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other Expense By Nature", "negatedLabel": "Other expenses" } } }, "localname": "OtherExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceIncome": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10080.0, "parentTag": "us-gaap_OtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } }, "en-us": { "role": { "label": "Other Finance Income", "terseLabel": "Others" } } }, "localname": "OtherFinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherGainsLosses": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10020.0, "parentTag": "legn_OtherIncomeAndGains", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Gains Losses", "totalLabel": "Other gains" } } }, "localname": "OtherGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIncome": { "auth_ref": [ "r1", "r2", "r106" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10080.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income and gains" } } }, "localname": "OtherIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other Noncurrent Assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10110.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } }, "en-us": { "role": { "label": "Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10320.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Other Noncurrent Nonfinancial Assets", "terseLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentNonfinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails": { "order": 10030.0, "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Payables", "terseLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r31" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": 10020.0, "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r32" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10040.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other Reserves", "terseLabel": "Reserves" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r57" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10200.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other Tax Effects For Reconciliation Between Accounting Profit And Tax Expense Income", "terseLabel": "Others" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10100.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other Tax Rate Effects For Reconciliation Between Accounting Profit And Tax Expense Income", "terseLabel": "Others, effective tax rate" } } }, "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_OutstandingCommitmentsMadeByEntityRelatedPartyTransactions": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding commitments made by the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Outstanding Commitments Made By Entity Related Party Transactions", "terseLabel": "Outstanding due from related party" } } }, "localname": "OutstandingCommitmentsMadeByEntityRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par Value Per Share", "terseLabel": "Price per share" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesParentheticalDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10150.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments Of Lease Liabilities Classified As Financing Activities", "negatedLabel": "Principal portion of lease payments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Postemployment Benefit Expense Defined Contribution Plans", "terseLabel": "Pension scheme contributions (defined contribution schemes)" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Prepayments": { "auth_ref": [ "r31" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails": { "order": 10020.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": 10050.0, "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } }, "en-us": { "role": { "label": "Prepayments", "terseLabel": "Prepaid expenses", "verboseLabel": "Prepayments" } } }, "localname": "Prepayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Presentation Of Leases For Lessee [Abstract]" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProbabilityOfDefaultAxis": { "auth_ref": [ "r252", "r266" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Probability Of Default [Axis]", "terseLabel": "Probability of default [axis]" } } }, "localname": "ProbabilityOfDefaultAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r145" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10060.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds From Borrowings Classified As Financing Activities", "terseLabel": "Proceeds from loans from related parties" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": { "auth_ref": [ "r144" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10230.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets", "terseLabel": "Proceeds from disposal of property, plant and equipment" } } }, "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r148" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10130.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds From Exercise Of Options", "terseLabel": "Proceeds from exercise of share options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } }, "en-us": { "role": { "label": "Proceeds From Exercise Of Warrants", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r148" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10090.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds From Issue Of Ordinary Shares", "terseLabel": "Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfPreferenceShares": { "auth_ref": [ "r148" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10080.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of preference shares. [Refer: Preference shares [member]]" } }, "en-us": { "role": { "label": "Proceeds From Issue Of Preference Shares", "terseLabel": "Proceeds from convertible redeemable preferred shares" } } }, "localname": "ProceedsFromIssueOfPreferenceShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r206", "r279" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products And Services [Axis]", "terseLabel": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r206", "r279" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products And Services [Member]", "terseLabel": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r4", "r40", "r149", "r172", "r174", "r178", "r274", "r276", "r288", "r300" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": { "order": 10010.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10040.0, "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit Loss", "terseLabel": "Loss for the year", "totalLabel": "LOSS FOR THE YEAR" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss [Abstract]" } } }, "localname": "ProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit Loss Attributable To [Abstract]", "terseLabel": "Attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r43" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Attributable To Owners Of Parent", "terseLabel": "Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation", "totalLabel": "Ordinary equity holders of the parent" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentSummaryOfCalculationsOfBasicAndDilutedLossPerShareDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r238", "r274", "r276" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10460.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10050.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit Loss Before Tax", "terseLabel": "Loss before tax", "totalLabel": "LOSS BEFORE TAX" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r17", "r72" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10270.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property Plant And Equipment", "periodEndLabel": "Property, plant and equipment, ending balance", "periodStartLabel": "Property, plant and equipment, beginning balance", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r73", "r121", "r215" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property Plant And Equipment [Member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "auth_ref": [ "r110", "r113", "r177" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Proportion Of Ownership Interest In Subsidiary", "terseLabel": "Percentage of equity interest attributable to the Company" } } }, "localname": "ProportionOfOwnershipInterestInSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10170.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase Of Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10160.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase Of Property Plant And Equipment Classified As Investing Activities", "negatedLabel": "Purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Purchases Of Goods Related Party Transactions", "terseLabel": "Purchases from related parties" } } }, "localname": "PurchasesOfGoodsRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of property and other assets purchased by the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Purchases Of Property And Other Assets Related Party Transactions", "terseLabel": "Purchase of equipment" } } }, "localname": "PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r195", "r196", "r197", "r230", "r259", "r289" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r195", "r196", "r197", "r230", "r259", "r289" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [Member]", "terseLabel": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "auth_ref": [ "r198", "r201" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } }, "en-us": { "role": { "label": "Receivables From Contracts With Customers", "terseLabel": "Advances received from customers" } } }, "localname": "ReceivablesFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReceivablesFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables From Contracts With Customers [Abstract]", "terseLabel": "Revenue from contracts with customer" } } }, "localname": "ReceivablesFromContractsWithCustomersAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RelatedPartiesMember": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Related Parties [Member]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RentalIncome": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised from rental activities." } }, "en-us": { "role": { "label": "Rental Income", "terseLabel": "Rental income recognised" } } }, "localname": "RentalIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r146" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10070.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Repayments Of Borrowings Classified As Financing Activities", "negatedLabel": "Repayments of loans from related parties" } } }, "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r133" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10090.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research And Development Expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r9", "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve Of Exchange Differences On Translation [Member]", "terseLabel": "Foreign Currency Translation Reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve Of Sharebased Payments [Member]", "terseLabel": "Share-based Compensation Reserves" } } }, "localname": "ReserveOfSharebasedPaymentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r32", "r53" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained Earnings", "terseLabel": "Reserves/(deficits)" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r8", "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings/(Accumulated Losses)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r45", "r178", "r184", "r238", "r272", "r275", "r279", "r280", "r283" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r199", "r200" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10070.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue From Contracts With Customers", "terseLabel": "REVENUE", "totalLabel": "Revenue from contracts with customer" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue From Performance Obligations Satisfied Or Partially Satisfied In Previous Periods", "terseLabel": "Revenue recognized from performance obligation satisfied in previous periods" } } }, "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromSaleOfGoods": { "auth_ref": [ "r10" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails": { "order": 10010.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue From Sale Of Goods", "terseLabel": "Sales of goods" } } }, "localname": "RevenueFromSaleOfGoods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]" } }, "en-us": { "role": { "label": "Revenue From Sale Of Goods Related Party Transactions", "terseLabel": "Sales of materials to related parties" } } }, "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue That Was Included In Contract Liability Balance At Beginning Of Period", "terseLabel": "Revenue recognized that was included in contract liabilities at the beginning of the reporting period" } } }, "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Reversal of impairment loss recognised in profit or loss; Trade receivables]" } }, "en-us": { "role": { "label": "Reversal Of Impairment Loss Recognised In Profit Or Loss Trade Receivables", "negatedLabel": "Impairment losses reversed" } } }, "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesSummaryOfMovementsInLossAllowanceForImpairmentOfTradeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r214" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10290.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Rightofuse Assets", "periodEndLabel": "Ending balance", "periodStartLabel": "Right-of-use assets, net of accumulated depreciation, beginning balance", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesOfPropertyAndOtherAssetsRelatedPartyTransactions": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of property and other assets sold by the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Sales Of Property And Other Assets Related Party Transactions", "terseLabel": "Sale of equipment" } } }, "localname": "SalesOfPropertyAndOtherAssetsRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ServiceConcessionArrangementsAxis": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Service Concession Arrangements [Axis]", "terseLabel": "Service concession arrangements [axis]" } } }, "localname": "ServiceConcessionArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ServiceConcessionArrangementsMember": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "This member stands for arrangements in which an entity (the operator) may enter into an arrangement with another entity (the grantor) to provide services that give the public access to major economic and social facilities. The grantor may be a public or private sector entity, including a governmental body. Examples of service concession arrangements involve water treatment and supply facilities, motorways, car parks, tunnels, bridges, airports and telecommunication networks. Examples of arrangements that are not service concession arrangements include an entity outsourcing the operation of its internal services (for example, employee cafeteria, building maintenance, and accounting or information technology functions). It also represents the standard value for the 'Service concession arrangements' axis if no other member is used. [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Service Concession Arrangements [Member]", "terseLabel": "Service concession arrangements [member]" } } }, "localname": "ServiceConcessionArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ServicesReceivedRelatedPartyTransactions": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Services Received Related Party Transactions", "terseLabel": "Consideration paid for shared services" } } }, "localname": "ServicesReceivedRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions": { "auth_ref": [ "r104" ], "lang": { "en": { "role": { "documentation": "The amount of liabilities settled on behalf of the entity by a related party in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Settlement Of Liabilities On Behalf Of Entity By Related Party Related Party Transactions", "terseLabel": "Settlement of balance due to related party" } } }, "localname": "SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r7" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share Issue Related Cost", "terseLabel": "Issuance costs" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share Premium [Member]", "terseLabel": "Share Premium" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Sharebased Payment Arrangements [Member]", "terseLabel": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Shortterm Deposits Classified As Cash Equivalents", "verboseLabel": "Less: Pledged deposits" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r111", "r114", "r188" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Significant Investments In Subsidiaries [Axis]", "terseLabel": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Changes In Equity [Abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Line Items]", "terseLabel": "Statement Of Changes In Equity [Line Items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement Of Changes In Equity [Table]", "terseLabel": "Statement Of Changes In Equity [Table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Profit Or Loss And Other Comprehensive Income [Abstract]" } } }, "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_SubsidiariesMember": { "auth_ref": [ "r97", "r111", "r114", "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for entities that are controlled by another entity." } }, "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Subsidiaries" } } }, "localname": "SubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r57" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10140.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax Effect Of Expense Not Deductible In Determining Taxable Profit Tax Loss", "terseLabel": "Effect of non-deductible expenses" } } }, "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r57" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10120.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax Effect Of Foreign Tax Rates", "terseLabel": "Effect of tax rate differences in other countries and regions" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10070.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]" } }, "en-us": { "role": { "label": "Tax Rate Effect Of Adjustments For Current Tax Of Prior Periods", "terseLabel": "Prior year true up, effective tax rate" } } }, "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10040.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax Rate Effect Of Expense Not Deductible In Determining Taxable Profit Tax Loss", "terseLabel": "Effect of non-deductible expenses, effective tax rate" } } }, "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TaxRateEffectOfForeignTaxRates": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10020.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax Rate Effect Of Foreign Tax Rates", "terseLabel": "Effect of tax rate differences in other countries and regions" } } }, "localname": "TaxRateEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TaxRateEffectOfTaxLosses": { "auth_ref": [ "r58" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10050.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax Rate Effect Of Tax Losses", "terseLabel": "Tax losses and deductible temporary differences not recognized, effective tax rate" } } }, "localname": "TaxRateEffectOfTaxLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary Difference Unused Tax Losses And Unused Tax Credits [Axis]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary Difference Unused Tax Losses And Unused Tax Credits [Member]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r195", "r196", "r197", "r230", "r259", "r289" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top Of Range [Member]", "terseLabel": "Top of Range" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfFairValueOfEquitySettledShareOptionsGrantedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherPayables": { "auth_ref": [ "r21" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": 10010.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } }, "en-us": { "role": { "label": "Trade And Other Payables", "terseLabel": "Trade and notes payables" } } }, "localname": "TradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade And Other Payables [Abstract]" } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherPayablesToRelatedParties": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payables due to related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Trade And Other Payables To Related Parties", "terseLabel": "Other payables due to related parties" } } }, "localname": "TradeAndOtherPayablesToRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r33" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails": { "order": 10010.0, "parentTag": "legn_TradeAndNotesPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade And Other Payables To Trade Suppliers", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade And Other Receivables [Abstract]" } } }, "localname": "TradeAndOtherReceivablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r10", "r247", "r251", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Trade Receivables [Member]", "terseLabel": "Trade Receivables" } } }, "localname": "TradeReceivablesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "auth_ref": [ "r204" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Transaction Price Allocated To Remaining Performance Obligations", "terseLabel": "Amounts expected to be recognized as revenue" } } }, "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r192" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Into Level3 Of Fair Value Hierarchy Assets", "terseLabel": "Fair value, measurement asset transfers into level 3" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Into Level3 Of Fair Value Hierarchy Liabilities", "terseLabel": "Fair value, measurement liability, transfers into level 3" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level1 Into Level2 Of Fair Value Hierarchy Assets", "terseLabel": "Fair value, assets, level 1 to level 2 transfers" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level1 Into Level2 Of Fair Value Hierarchy Liabilities", "terseLabel": "Fair value, liabilities, level 1 to level 2 transfers" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level2 Into Level1 Of Fair Value Hierarchy Assets", "terseLabel": "Fair value, assets, level 2 to level 1 transfers" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level2 Into Level1 Of Fair Value Hierarchy Liabilities", "terseLabel": "Fair value, liabilities, level 2 to level 1 transfers" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level3 Of Fair Value Hierarchy Assets", "terseLabel": "Fair value, measurement asset transfers out of level 3" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r192" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers Out Of Level3 Of Fair Value Hierarchy Liabilities", "terseLabel": "Fair value, measurement liability, transfers out of level 3" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersUnderLicenseAgreementsToEntityRelatedPartyTransactions": { "auth_ref": [ "r103" ], "lang": { "en": { "role": { "documentation": "The amount of transfers under licence agreements to the entity in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Transfers Under License Agreements To Entity Related Party Transactions", "terseLabel": "License and collaboration revenue" } } }, "localname": "TransfersUnderLicenseAgreementsToEntityRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r240", "r245", "r246", "r290", "r291", "r292", "r294" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Risks [Axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r240", "r245", "r246", "r290", "r291", "r292", "r294" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Types Of Risks [Member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Sharebased Payment Arrangements [Axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Undiscounted Operating Lease Payments To Be Received", "terseLabel": "Undiscounted minimum lease payments receivables in future periods under non-cancellable operating leases" } } }, "localname": "UndiscountedOperatingLeasePaymentsToBeReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfUndiscountedMinimumLeasePaymentsReceivablesInFuturePeriodsUnderNonCancellableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r59" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails": { "order": 10020.0, "parentTag": "legn_DeferredTaxAssetNotYetRecognized", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Unused Tax Losses For Which No Deferred Tax Asset Recognised", "terseLabel": "Tax losses" } } }, "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ValueAddedTaxReceivables": { "auth_ref": [ "r31" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails": { "order": 10010.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": 10040.0, "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } }, "en-us": { "role": { "label": "Value Added Tax Receivables", "terseLabel": "Value-added Tax (\u201cVAT\u201d) recoverable", "verboseLabel": "VAT recoverable" } } }, "localname": "ValueAddedTaxReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_VehiclesMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Vehicles [Member]", "terseLabel": "Transportation Equipment" } } }, "localname": "VehiclesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages And Salaries", "terseLabel": "Wages and salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WarrantLiability": { "auth_ref": [ "r23" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": 10030.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of warrant liabilities." } }, "en-us": { "role": { "label": "Warrant Liability", "periodEndLabel": "At December 31, 2021", "periodStartLabel": "At January 1, 2021", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiability", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityScheduleOfMovementOfWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WarrantyContingentLiabilityMember": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "This member stands for a contingent liability for estimated costs of making good under warranties for products sold. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Warranty Contingent Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantyContingentLiabilityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Sharebased Payment Arrangement2019", "terseLabel": "Weighted average grant date fair value, Vested during the year" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Sharebased Payment Arrangement2019", "terseLabel": "Weighted average grant date fair value, Forfeited during the year" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Other Equity Instruments Granted In Sharebased Payment Arrangement2019", "terseLabel": "Weighted average grant date fair value, Granted during the year" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Sharebased Payment Arrangement2019", "periodEndLabel": "Weighted average grant date fair value, Outstanding at December 31", "periodStartLabel": "Weighted average grant date fair value, Outstanding at January 1" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Exercisable In Sharebased Payment Arrangement2019", "terseLabel": "Exercisable at December 31, weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Exercised In Sharebased Payment Arrangement2019", "terseLabel": "Exercised during the year, weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r224" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Forfeited In Sharebased Payment Arrangement2019", "terseLabel": "Forfeited during the year, weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r223" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Granted In Sharebased Payment Arrangement2019", "terseLabel": "Granted during the year, weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "auth_ref": [ "r229" ], "lang": { "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options In Sharebased Payment Arrangement Exercised During Period At Date Of Exercise2019", "terseLabel": "Weighted average share price for share options in share-based payment arrangement exercised during period" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r222", "r226" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Exercise Price Of Share Options Outstanding In Sharebased Payment Arrangement2019", "periodEndLabel": "At December 31, weighted average exercise price", "periodStartLabel": "At January 1, weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfShareOptionsOutstandingUnderSchemeDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Fair Value At Measurement Date Other Equity Instruments Granted", "terseLabel": "Fair value of share options granted" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Fair Value At Measurement Date Share Options Granted", "terseLabel": "Fair value of share options granted" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r230" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options2019", "terseLabel": "Weighted-average remaining contractual life for outstanding RSUs granted" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r232" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted Average Share Price Share Options Granted2019", "terseLabel": "Fair value per share of options granted" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r117" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted Average Shares", "terseLabel": "Weighted average number of ordinary shares issued", "verboseLabel": "Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossPerShareAttributableToOrdinaryEquityHoldersOfParentSummaryOfCalculationsOfBasicAndDilutedLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "legn_AccruedExpense": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails": { "order": 10020.0, "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expense.", "label": "Accrued Expense", "terseLabel": "Accrued expense" } } }, "localname": "AccruedExpense", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "legn_AccruedPayroll": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails": { "order": 10010.0, "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued payroll.", "label": "Accrued Payroll", "terseLabel": "Accrued payroll" } } }, "localname": "AccruedPayroll", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "legn_AdditionInPledgedDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10260.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Addition in pledged deposits.", "label": "Addition In Pledged Deposits", "negatedLabel": "Addition in pledged deposits" } } }, "localname": "AdditionInPledgedDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdditionInTimeDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10240.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Addition in time deposits.", "label": "Addition In Time Deposits", "negatedLabel": "Addition in time deposits" } } }, "localname": "AdditionInTimeDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdditionalMilestonePaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional milestone payment receivable.", "label": "Additional Milestone Payment Receivable", "terseLabel": "Additional milestone payment receivable" } } }, "localname": "AdditionalMilestonePaymentReceivable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_AdditionalShareCapitalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional share capital amount.", "label": "Additional Share Capital Amount", "terseLabel": "Additional share capital amount" } } }, "localname": "AdditionalShareCapitalAmount", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentForFairValueLossOfWarrantLiability": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10540.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for fair value loss of warrant liability.", "label": "Adjustment For Fair Value Loss Of Warrant Liability", "terseLabel": "Fair value loss of warrant liability" } } }, "localname": "AdjustmentForFairValueLossOfWarrantLiability", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10370.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease increase in prepayments other receivable other assets.", "label": "Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets", "terseLabel": "(Increase)/decrease in prepayments, other receivables and other assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentsForDepreciationOfRightOfUseAssets": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10530.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation of right-of-use assets.", "label": "Adjustments For Depreciation Of Right Of Use Assets", "terseLabel": "Depreciation of right-of-use assets" } } }, "localname": "AdjustmentsForDepreciationOfRightOfUseAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentsForFairValueGainLossOfConvertibleRedeemablePreferredShares": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10550.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for fair value gain loss of convertible redeemable preferred shares.", "label": "Adjustments For Fair Value Gain Loss Of Convertible Redeemable Preferred Shares", "terseLabel": "Fair value loss of convertible redeemable preferred shares" } } }, "localname": "AdjustmentsForFairValueGainLossOfConvertibleRedeemablePreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentsForGovernmentGrantReceived": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10400.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for government grant received.", "label": "Adjustments For Government Grant Received", "terseLabel": "Government grant received" } } }, "localname": "AdjustmentsForGovernmentGrantReceived", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10430.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in other non current liabilities.", "label": "Adjustments For Increase Decrease In Other Non Current Liabilities", "terseLabel": "(Decrease)/increase in other non-current liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_AdvancePaymentsForPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10280.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advance payments for property, plant and equipment.", "label": "Advance Payments For Property Plant And Equipment", "terseLabel": "Advance payments for property, plant and equipment" } } }, "localname": "AdvancePaymentsForPropertyPlantAndEquipment", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American depositary shares.", "label": "American Depositary Shares [Member]", "terseLabel": "American Depositary Shares" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "legn_ApplicableTaxRateOnRemainingAssessableProfits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Applicable tax rate on remaining assessable profits.", "label": "Applicable Tax Rate On Remaining Assessable Profits", "terseLabel": "Income tax rate on remaining assessable profits" } } }, "localname": "ApplicableTaxRateOnRemainingAssessableProfits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_AuthorisedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorised.", "label": "Authorised [Abstract]", "terseLabel": "Authorized:" } } }, "localname": "AuthorisedAbstract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails" ], "xbrltype": "stringItemType" }, "legn_AuthorizedShareCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Authorized share capital.", "label": "Authorized Share Capital", "terseLabel": "2,000,000,000 shares of US$0.0001 each" } } }, "localname": "AuthorizedShareCapital", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfSharesDetails" ], "xbrltype": "monetaryItemType" }, "legn_BasisOfPreparationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of Preparation.", "label": "Basis Of Preparation [Abstract]" } } }, "localname": "BasisOfPreparationAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_BinomialModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Binomial model.", "label": "Binomial Model [Member]", "terseLabel": "Binomial Model" } } }, "localname": "BinomialModelMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_BorrowingsRepaymentDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, repayment date.", "label": "Borrowings Repayment Date", "terseLabel": "Borrowings, repayment date" } } }, "localname": "BorrowingsRepaymentDate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "legn_CARTITUDE1ClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARTITUDE-1 clinical trial.", "label": "C A R T I T U D E1 Clinical Trial [Member]", "terseLabel": "CARTITUDE-1 Clinical Trial" } } }, "localname": "CARTITUDE1ClinicalTrialMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_CapitalGearingRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gearing ratio.", "label": "Capital Gearing Ratio", "terseLabel": "Gearing ratio" } } }, "localname": "CapitalGearingRatio", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMonitoringCapitalUsingGearingRatioDetails" ], "xbrltype": "percentItemType" }, "legn_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents.", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents as stated in statement of cash flows.", "label": "Cash And Cash Equivalents As Stated In Statement Of Cash Flows", "terseLabel": "Cash and cash equivalents as stated in the statement of cash flows" } } }, "localname": "CashAndCashEquivalentsAsStatedInStatementOfCashFlows", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents as stated in statement of financial position.", "label": "Cash And Cash Equivalents As Stated In Statement Of Financial Position", "terseLabel": "Cash and cash equivalents as stated in the statement of financial position" } } }, "localname": "CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_CashAndCashEquivalentsMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maturity of an instrument classified as cash or a cash equivalent.", "label": "Cash And Cash Equivalents Maturity", "terseLabel": "Cash and cash equivalents maturity, months" } } }, "localname": "CashAndCashEquivalentsMaturity", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_CashOutflowForLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash outflow for leases.", "label": "Cash Outflow For Leases [Abstract]" } } }, "localname": "CashOutflowForLeasesAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_CashOutflowForLeasesWithinFinancingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails": { "order": 10020.0, "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow for leases within financing activities.", "label": "Cash Outflow For Leases Within Financing Activities", "terseLabel": "Within financing activities" } } }, "localname": "CashOutflowForLeasesWithinFinancingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "legn_CashOutflowForLeasesWithinOperatingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails": { "order": 10010.0, "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow for leases within operating activities.", "label": "Cash Outflow For Leases Within Operating Activities", "terseLabel": "Within operating activities" } } }, "localname": "CashOutflowForLeasesWithinOperatingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "legn_CashOutflowForShortTermLeases": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails": { "order": 10030.0, "parentTag": "ifrs-full_CashOutflowForLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow for short term leases.", "label": "Cash Outflow For Short Term Leases", "terseLabel": "Short-term leases" } } }, "localname": "CashOutflowForShortTermLeases", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10200.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts of investment income classified as investing activities.", "label": "Cash Receipts Of Investment Income Classified As Investing Activities", "terseLabel": "Cash receipts of investment income" } } }, "localname": "CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_CashReceivedFromWithdrawalOfFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10190.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from withdrawal of financial assets at fair value through profit or loss.", "label": "Cash Received From Withdrawal Of Financial Assets At Fair Value Through Profit Or Loss", "terseLabel": "Cash received from withdrawal of financial assets measured at fair value through profit or loss" } } }, "localname": "CashReceivedFromWithdrawalOfFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_ChangesFromFinancingCashFlowsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes from financing cash flows shares.", "label": "Changes From Financing Cash Flows Shares", "terseLabel": "Changes from financing cash flows, shares" } } }, "localname": "ChangesFromFinancingCashFlowsShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "sharesItemType" }, "legn_CiltaCelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cilta-cel.", "label": "Cilta Cel [Member]", "terseLabel": "Cilta-cel" } } }, "localname": "CiltaCelMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_CommercialPaperIssuedByFinancialInstitutionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial paper issued by financial institution.", "label": "Commercial Paper Issued By Financial Institution [Member]", "terseLabel": "Commercial Paper Issued by Financial Institution" } } }, "localname": "CommercialPaperIssuedByFinancialInstitutionMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_CompensationFeeForTerminationOfServiceAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Compensation fee for termination of service agreement.", "label": "Compensation Fee For Termination Of Service Agreement", "terseLabel": "Compensation fee for termination of service agreement" } } }, "localname": "CompensationFeeForTerminationOfServiceAgreement", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer and office equipment.", "label": "Computer And Office Equipment [Member]", "terseLabel": "Computer and Office Equipment" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "legn_ConstructionPaymentPayableInFuture": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Construction payment payable in future.", "label": "Construction Payment Payable In Future", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionPaymentPayableInFuture", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCapitalCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "legn_ContractLiabilityExchangeRealignment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability exchange realignment.", "label": "Contract Liability Exchange Realignment", "terseLabel": "Exchange realignment" } } }, "localname": "ContractLiabilityExchangeRealignment", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesSummaryOfMovementsInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_ContractLiabilityPaymentsReceivedDueToReceive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract liability payments received/due to receive.", "label": "Contract Liability Payments Received Due To Receive", "terseLabel": "Payments received/due to receive" } } }, "localname": "ContractLiabilityPaymentsReceivedDueToReceive", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesSummaryOfMovementsInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_ContractLiabilityTransferredToRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability transferred to revenue.", "label": "Contract Liability Transferred To Revenue", "negatedLabel": "Transferred to revenue" } } }, "localname": "ContractLiabilityTransferredToRevenue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesSummaryOfMovementsInContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_ConvertibleRedeemablePreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible redeemable preferred shares.", "label": "Convertible Redeemable Preferred Shares [Member]", "terseLabel": "Convertible Redeemable Preferred Shares" } } }, "localname": "ConvertibleRedeemablePreferredSharesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "domainItemType" }, "legn_CreditPeriodOfTradeReceivables": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit period of trade receivables.", "label": "Credit Period Of Trade Receivables", "terseLabel": "Credit period of trade receivables" } } }, "localname": "CreditPeriodOfTradeReceivables", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_DateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date of incorporation.", "label": "Date Of Incorporation", "terseLabel": "Date of incorporation" } } }, "localname": "DateOfIncorporation", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "legn_DecreaseInPledgedDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10270.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in pledged deposits.", "label": "Decrease In Pledged Deposits", "terseLabel": "Decrease in pledged deposits" } } }, "localname": "DecreaseInPledgedDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_DecreaseInTimeDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10250.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in time deposits.", "label": "Decrease In Time Deposits", "terseLabel": "Decrease in time deposits" } } }, "localname": "DecreaseInTimeDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_DeferredGovernmentGrant": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10590.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred government grant.", "label": "Deferred Government Grant", "terseLabel": "Deferred government grant" } } }, "localname": "DeferredGovernmentGrant", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_DeferredTaxAssetNotYetRecognized": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax asset not yet recognized.", "label": "Deferred Tax Asset Not Yet Recognized", "terseLabel": "Unrecognized deferred tax assets", "totalLabel": "Deferred tax asset not yet recognized" } } }, "localname": "DeferredTaxAssetNotYetRecognized", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxSummaryOfItemsWithRespectToDeferredTaxAssetsHaveNotBeenRecognizedDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_DeferredTaxCarryBackPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax carry back period.", "label": "Deferred Tax Carry Back Period", "terseLabel": "Deferred tax carry back period" } } }, "localname": "DeferredTaxCarryBackPeriod", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_DeferredTaxCarryForwardPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax carry forward period.", "label": "Deferred Tax Carry Forward Period", "terseLabel": "Deferred tax carry forward period" } } }, "localname": "DeferredTaxCarryForwardPeriod", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_DepositsFromBank": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits from bank.", "label": "Deposits From Bank", "terseLabel": "Time deposits" } } }, "localname": "DepositsFromBank", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "monetaryItemType" }, "legn_DescriptionOfAccountingPolicyForContractAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for contract assets explanatory.", "label": "Description Of Accounting Policy For Contract Assets Explanatory", "terseLabel": "Contract assets" } } }, "localname": "DescriptionOfAccountingPolicyForContractAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_DescriptionOfAccountingPolicyForContractLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for contract liabilities.", "label": "Description Of Accounting Policy For Contract Liabilities Explanatory", "terseLabel": "Contract liabilities" } } }, "localname": "DescriptionOfAccountingPolicyForContractLiabilitiesExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_DescriptionOfAccountingPolicyForImpactOfCovid19Explanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for impact of covid 19.", "label": "Description Of Accounting Policy For Impact Of Covid19 Explanatory", "terseLabel": "Impact of covid-19" } } }, "localname": "DescriptionOfAccountingPolicyForImpactOfCovid19Explanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_DescriptionOfAccountingPolicyForInvestmentsAndOtherFinancialAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for investments and other financial assets.", "label": "Description Of Accounting Policy For Investments And Other Financial Assets Explanatory", "terseLabel": "Investments and other financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForInvestmentsAndOtherFinancialAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_DescriptionOfAutomaticConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of automatic conversion.", "label": "Description Of Automatic Conversion", "terseLabel": "Automatic conversion, description" } } }, "localname": "DescriptionOfAutomaticConversion", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_DescriptionOfRecognizeShorttermLeasesAndLeasesOfLowvalueAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of recognize short-term leases and leases of low-value assets.", "label": "Description Of Recognize Shortterm Leases And Leases Of Lowvalue Assets", "terseLabel": "Description of recognize a short-term leases" } } }, "localname": "DescriptionOfRecognizeShorttermLeasesAndLeasesOfLowvalueAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_DescriptionOfRedemptionRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of redemption rights.", "label": "Description Of Redemption Rights", "terseLabel": "Redemption rights, description" } } }, "localname": "DescriptionOfRedemptionRights", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detailed disclosure of reconciliation of tax expense applicable to loss before tax at the statutory rate.", "label": "Detailed Disclosure Of Reconciliation Of Tax Expense Applicable To Loss Before Tax At Statutory Rate", "terseLabel": "Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates" } } }, "localname": "DetailedDisclosureOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "legn_DetailedDisclosureOfTaxCharges": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detailed disclosure of tax charges.", "label": "Detailed Disclosure Of Tax Charges", "terseLabel": "Summary of Tax Charges" } } }, "localname": "DetailedDisclosureOfTaxCharges", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure fair value measurement hierarchy of financial instruments.", "label": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]", "terseLabel": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]" } } }, "localname": "DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure fair value measurement hierarchy of financial instruments.", "label": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]", "terseLabel": "Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Table]" } } }, "localname": "DisclosureFairValueMeasurementHierarchyOfFinancialInstrumentsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueMeasurementHierarchyOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of amounts incurred for compensation of key management personnel.", "label": "Disclosure Of Amounts Incurred For Compensation Of Key Management Personnel Explanatory", "terseLabel": "Summary of Compensation of Key Management Personnel" } } }, "localname": "DisclosureOfAmountsIncurredForCompensationOfKeyManagementPersonnelExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfBasisOfPreparationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Basis of preparation.", "label": "Disclosure Of Basis Of Preparation Explanatory", "terseLabel": "Basis of Preparation" } } }, "localname": "DisclosureOfBasisOfPreparationExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureBasisOfPreparation" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfCapitalCommitmentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of capital commitments.", "label": "Disclosure Of Capital Commitments Explanatory", "terseLabel": "Summary of Capital Commitments" } } }, "localname": "DisclosureOfCapitalCommitmentsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits.", "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits.", "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]", "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash and cash equivalents, time deposits and pledged deposits.", "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]", "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfContractLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of contract liabilities.", "label": "Disclosure Of Contract Liabilities", "terseLabel": "Contract Liabilities" } } }, "localname": "DisclosureOfContractLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilities" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfConvertibleRedeemablePreferredSharesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of convertible redeemable preferred shares.", "label": "Disclosure Of Convertible Redeemable Preferred Shares Explanatory", "terseLabel": "Convertible Redeemable Preferred Shares" } } }, "localname": "DisclosureOfConvertibleRedeemablePreferredSharesExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredShares" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDeferredGovernmentGrantsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of deferred government grants.", "label": "Disclosure Of Deferred Government Grants Explanatory", "terseLabel": "Summary of Deferred Government Grants" } } }, "localname": "DisclosureOfDeferredGovernmentGrantsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureGovernmentGrantsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Time Deposits And Pledged Deposits Explanatory", "terseLabel": "Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about deferred tax assets.", "label": "Disclosure Of Detailed Information About Deferred Tax Assets Explanatory", "terseLabel": "Summary of Items with Respect to, Deferred Tax Assets have not been Recognized" } } }, "localname": "DisclosureOfDetailedInformationAboutDeferredTaxAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutInventoriesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about inventories.", "label": "Disclosure Of Detailed Information About Inventories Explanatory", "terseLabel": "Summary of Inventories" } } }, "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about lease liabilities.", "label": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]", "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]" } } }, "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about lease liabilities.", "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]", "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]" } } }, "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about monitoring capital using gearing ratio.", "label": "Disclosure Of Detailed Information About Monitoring Capital Using Gearing Ratio Explanatory", "terseLabel": "Summary of Monitoring Capital Using Gearing Ratio" } } }, "localname": "DisclosureOfDetailedInformationAboutMonitoringCapitalUsingGearingRatioExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other payables and accruals.", "label": "Disclosure Of Detailed Information About Other Payables And Accruals Explanatory", "terseLabel": "Summary of Other Payables and Accruals" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about prepayments, other receivables and other assets.", "label": "Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory", "terseLabel": "Summary of Prepayments, Other Receivables and Other Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about the sensitivity to reasonably possible change in exchange rates.", "label": "Disclosure Of Detailed Information About Sensitivity To Reasonably Possible Change In Exchange Rates Explanatory", "terseLabel": "Summary of Sensitivity to Reasonably Possible Change in Exchange Rates" } } }, "localname": "DisclosureOfDetailedInformationAboutSensitivityToReasonablyPossibleChangeInExchangeRatesExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about warrant liability explanatory.", "label": "Disclosure Of Detailed Information About Warrant Liability Explanatory", "terseLabel": "Schedule of Movement of Warrant Liability" } } }, "localname": "DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information of trade receivables.", "label": "Disclosure Of Detailed Information Of Trade Receivables Table [Text Block]", "terseLabel": "Summary of Trade Receivables" } } }, "localname": "DisclosureOfDetailedInformationOfTradeReceivablesTableTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfEstimatedUsefulLivesOfRightOfUseAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of estimated useful lives of right-of-use assets.", "label": "Disclosure Of Estimated Useful Lives Of Right Of Use Assets Explanatory", "terseLabel": "Summary of Estimated Useful Lives of Right-of-Use Assets" } } }, "localname": "DisclosureOfEstimatedUsefulLivesOfRightOfUseAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of fair value measurement of assets and liabilities.", "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfFairValueOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of fair value of financial instruments.", "label": "Disclosure Of Fair Value Of Financial Instruments [Abstract]" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of fair value valuation of warrant liability.", "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Abstract]" } } }, "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of fair value valuation of warrant liability.", "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]", "terseLabel": "Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]" } } }, "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfFairValueValuationOfWarrantLiabilityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of fair value valuation of warrant liability.", "label": "Disclosure Of Fair Value Valuation Of Warrant Liability [Table]", "terseLabel": "Disclosure Of Fair Value Valuation Of Warrant Liability [Table]" } } }, "localname": "DisclosureOfFairValueValuationOfWarrantLiabilityTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsSummaryOfFairValueValuationOfWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial assets measured at amortized cost explanatory.", "label": "Disclosure Of Financial Assets Measured At Amortized Cost Explanatory", "terseLabel": "Financial Assets Measured At Amortized Cost" } } }, "localname": "DisclosureOfFinancialAssetsMeasuredAtAmortizedCostExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCost" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfInformationAboutCondensedFinancialStatementsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about condensed financial statements.", "label": "Disclosure Of Information About Condensed Financial Statements Explanatory", "terseLabel": "Summary of Financial Assets Measured at Amortized Cost" } } }, "localname": "DisclosureOfInformationAboutCondensedFinancialStatementsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information of inputs used in fair value valuation of warrant liability.", "label": "Disclosure Of Information Of Inputs Used In Fair Value Valuation Of Warrant Liability Explanatory", "terseLabel": "Summary of Fair Value Valuation of Warrant Liability" } } }, "localname": "DisclosureOfInformationOfInputsUsedInFairValueValuationOfWarrantLiabilityExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFairValueAndFairValueHierarchyOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfIntangibleAssetsAmortizationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of intangible assets amortization.", "label": "Disclosure Of Intangible Assets Amortization Explanatory", "terseLabel": "Summary of Intangible Assets Amortised" } } }, "localname": "DisclosureOfIntangibleAssetsAmortizationExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of movements in the company's share capital and share premium explanatory.", "label": "Disclosure Of Movements In Company S Share Capital And Share Premium Explanatory", "terseLabel": "Summary of Movements in the Company's Share Capital and Share Premium" } } }, "localname": "DisclosureOfMovementsInCompanySShareCapitalAndSharePremiumExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfNonCurrentAssetInformationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of non-current asset Information.", "label": "Disclosure Of Non Current Asset Information [Text Block]", "terseLabel": "Summary of Non-current Assets" } } }, "localname": "DisclosureOfNonCurrentAssetInformationTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfNotesToConsolidatedStatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of notes to the consolidated statement of cash flows.", "label": "Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]" } } }, "localname": "DisclosureOfNotesToConsolidatedStatementOfCashFlowsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfNotesToConsolidatedStatementOfCashFlowsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of notes to consolidated statement of cash flows.", "label": "Disclosure Of Notes To Consolidated Statement Of Cash Flows [Line Items]", "terseLabel": "Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]" } } }, "localname": "DisclosureOfNotesToConsolidatedStatementOfCashFlowsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfNotesToConsolidatedStatementOfCashFlowsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of notes to consolidated statement of cash Flows.", "label": "Disclosure Of Notes To Consolidated Statement Of Cash Flows [Table]", "terseLabel": "Disclosure Of Notes To Consolidated Statement Of Cash Flows [Table]" } } }, "localname": "DisclosureOfNotesToConsolidatedStatementOfCashFlowsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfOtherIncomeAndGainsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income and gains.", "label": "Disclosure Of Other Income And Gains [Abstract]" } } }, "localname": "DisclosureOfOtherIncomeAndGainsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other noncurrent assets table text block.", "label": "Disclosure Of Other Noncurrent Assets Table [Text Block]", "terseLabel": "Summary of Other Non-Current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherNonCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfOtherPayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other payables and accruals.", "label": "Disclosure Of Other Payables And Accruals [Abstract]" } } }, "localname": "DisclosureOfOtherPayablesAndAccrualsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfOtherPayablesAndAccrualsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other payables and accruals.", "label": "Disclosure Of Other Payables And Accruals Explanatory", "terseLabel": "Other Payables and Accruals" } } }, "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccruals" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfOutstandingBalancesWithRelatedPartiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of outstanding balances with related parties.", "label": "Disclosure Of Outstanding Balances With Related Parties Explanatory", "terseLabel": "Disclosure of Outstanding Balances with Related Parties Explanatory" } } }, "localname": "DisclosureOfOutstandingBalancesWithRelatedPartiesExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepayments, other receivables and other assets.", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]" } } }, "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepayments, other receivables and other assets.", "label": "Disclosure Of Prepayments Other Receivables And Other Assets Explanatory", "terseLabel": "Prepayments, Other Receivables and Other Assets" } } }, "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssets" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepayments, other receivables and other assets.", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]", "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]" } } }, "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of prepayments, other receivables and other assets.", "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]", "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]" } } }, "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "legn_DisclosureOfProfitLossBeforeTaxArrivedAfterChargingAndCreditingExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of profit loss before tax arrived after charging and crediting.", "label": "Disclosure Of Profit Loss Before Tax Arrived After Charging And Crediting Explanatory", "terseLabel": "Schedule of Profit Loss Before Tax Arrived After Charging and Crediting Explanatory" } } }, "localname": "DisclosureOfProfitLossBeforeTaxArrivedAfterChargingAndCreditingExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfRevenueOtherIncomeAndGainsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of revenue, other income and gains.", "label": "Disclosure Of Revenue Other Income And Gains Explanatory", "terseLabel": "Disclosure of Revenue, other income and gains Explanatory" } } }, "localname": "DisclosureOfRevenueOtherIncomeAndGainsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGains" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfSignificantAccountingJudgementsAndEstimatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting judgements and estimates.", "label": "Disclosure Of Significant Accounting Judgements And Estimates [Abstract]" } } }, "localname": "DisclosureOfSignificantAccountingJudgementsAndEstimatesAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of total cash outflow for leases included in statement of cash flows explanatory.", "label": "Disclosure Of Total Cash Outflow For Leases Included In Statement Of Cash Flows Explanatory", "terseLabel": "Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows" } } }, "localname": "DisclosureOfTotalCashOutflowForLeasesIncludedInStatementOfCashFlowsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfTradeAndOtherPayablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of trade and other payables table text block.", "label": "Disclosure Of Trade And Other Payables Table [Text Block]", "terseLabel": "Summary of Trade and Notes Payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesTableTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesTables" ], "xbrltype": "textBlockItemType" }, "legn_DisclosureOfWarrantLiabilityExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of warrant liability explanatory.", "label": "Disclosure Of Warrant Liability Explanatory", "terseLabel": "Warrant Liability" } } }, "localname": "DisclosureOfWarrantLiabilityExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiability" ], "xbrltype": "textBlockItemType" }, "legn_EmployeeBenefitExpenseExcludingDirectorsRemunerationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Expense Excluding Directors Remuneration [Abstract]", "terseLabel": "Employee benefit expense (including directors\u2019 remuneration):" } } }, "localname": "EmployeeBenefitExpenseExcludingDirectorsRemunerationAbstract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "stringItemType" }, "legn_EntireDisclosureOfFinanceCostsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of finance costs.", "label": "Entire Disclosure Of Finance Costs Explanatory", "terseLabel": "Finance Costs" } } }, "localname": "EntireDisclosureOfFinanceCostsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCosts" ], "xbrltype": "textBlockItemType" }, "legn_EntrustedLoanFromRelatedPartyTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Entrusted loan from a related party transactions.", "label": "Entrusted Loan From Related Party Transactions", "terseLabel": "Entrusted loan from a related party" } } }, "localname": "EntrustedLoanFromRelatedPartyTransactions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_EstimatedServicePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated service period.", "label": "Estimated Service Period", "terseLabel": "Estimated service period" } } }, "localname": "EstimatedServicePeriod", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_EstimatedTransactionPriceRelatedToContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated transaction price related to contract.", "label": "Estimated Transaction Price Related To Contract", "terseLabel": "Estimated total transaction price" } } }, "localname": "EstimatedTransactionPriceRelatedToContract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_ExerciseOfShareOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of share option.", "label": "Exercise Of Share Option", "terseLabel": "Exercise of share options" } } }, "localname": "ExerciseOfShareOption", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_ExerciseOfShareOptionNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of share option number of shares in issue.", "label": "Exercise Of Share Option Number Of Shares In Issue", "terseLabel": "Exercise of share options" } } }, "localname": "ExerciseOfShareOptionNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_ExercisePricePerOrdinaryShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per ordinary share.", "label": "Exercise Price Per Ordinary Share", "terseLabel": "Private placement purchase price per share" } } }, "localname": "ExercisePricePerOrdinaryShare", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "legn_ExpensesForIssuanceOfConvertibleRedeemablePreferredShares": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails": { "order": 10030.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses for issuance of convertible redeemable preferred shares.", "label": "Expenses For Issuance Of Convertible Redeemable Preferred Shares", "terseLabel": "Expenses for issuance of convertible redeemable preferred shares" } } }, "localname": "ExpensesForIssuanceOfConvertibleRedeemablePreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinanceCostsSummaryOfFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "legn_ExpensesRecognizedForShareOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized for share options.", "label": "Expenses Recognized For Share Options", "terseLabel": "Share option expense" } } }, "localname": "ExpensesRecognizedForShareOptions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_FairValueLossOfConvertibleRedeemablePreferredShareValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value loss of convertible redeemable preferred share value.", "label": "Fair Value Loss Of Convertible Redeemable Preferred Share Value", "terseLabel": "Fair value loss of the convertible redeemable preferred shares" } } }, "localname": "FairValueLossOfConvertibleRedeemablePreferredShareValue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_FairValueLossOfConvertibleRedeemablePreferredShares": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10140.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value loss of convertible redeemable preferred shares.", "label": "Fair Value Loss Of Convertible Redeemable Preferred Shares", "negatedLabel": "Fair value loss of convertible redeemable preferred shares", "terseLabel": "Fair value loss of the convertible redeemable preferred shares" } } }, "localname": "FairValueLossOfConvertibleRedeemablePreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "legn_FairValueLossOfWarrantsLiabilities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10130.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value loss of warrant liabilities.", "label": "Fair Value Loss Of Warrants Liabilities", "negatedLabel": "Fair value loss of warrant liability" } } }, "localname": "FairValueLossOfWarrantsLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "legn_FairValueLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value losses.", "label": "Fair Value Losses", "terseLabel": "Fair value loss" } } }, "localname": "FairValueLosses", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_FairValueLossesOfConvertibleRedeemablePreferredShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value loss of convertible redeemable preferred shares.", "label": "Fair Value Losses Of Convertible Redeemable Preferred Shares", "terseLabel": "Fair value loss of convertible redeemable preferred shares" } } }, "localname": "FairValueLossesOfConvertibleRedeemablePreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_FairValueOfWarrantLiabilityAssessed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrant liability assessed.", "label": "Fair Value Of Warrant Liability Assessed", "terseLabel": "Fair value of warrant liability assessed" } } }, "localname": "FairValueOfWarrantLiabilityAssessed", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_FinanceCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance costs.", "label": "Finance Costs [Abstract]" } } }, "localname": "FinanceCostsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_FinancialAssetsDiscountedBidYieldPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial assets discounted bid yield percentage.", "label": "Financial Assets Discounted Bid Yield Percentage", "terseLabel": "Discounted bid yield percentage" } } }, "localname": "FinancialAssetsDiscountedBidYieldPercentage", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial assets included in prepayments, other receivables and other assets.", "label": "Financial Assets Included In Prepayments Other Receivables And Other Assets [Member]", "terseLabel": "Financial Assets Included in Prepayments, Other Receivables and Other Assets" } } }, "localname": "FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_FinancialAssetsMeasuredAtAmortizedCost": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10230.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets measured at amortized cost.", "label": "Financial Assets Measured At Amortized Cost", "terseLabel": "Financial assets measured at amortized cost" } } }, "localname": "FinancialAssetsMeasuredAtAmortizedCost", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_FinancialAssetsMeasuredAtAmortizedCostMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial assets measured at amortized cost maturity date.", "label": "Financial Assets Measured At Amortized Cost Maturity Date", "terseLabel": "Financial assets measured at amortized cost maturity date" } } }, "localname": "FinancialAssetsMeasuredAtAmortizedCostMaturityDate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "legn_FinancialAssetsMeasuredAtAmortizedCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial assets measured at amortized cost.", "label": "Financial Assets Measured At Amortized Cost [Member]", "terseLabel": "Financial Assets Measured at Amortized Cost" } } }, "localname": "FinancialAssetsMeasuredAtAmortizedCostMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialAssetsMeasuredAtAmortizedCostSummaryOfFinancialAssetsMeasuredAtAmortizedCostDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial liabilities included in other payables and accruals.", "label": "Financial Liabilities Included In Other Payables And Accruals [Member]", "terseLabel": "Financial Liabilities included in Other Payables and Accruals" } } }, "localname": "FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "legn_FinancingFromFollowOnPublicOfferingNetOfIssuanceCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing from follow-on public offering, net of issuance cost.", "label": "Financing From Follow On Public Offering Net Of Issuance Cost", "terseLabel": "Financing from follow-on public offering, net of issuance cost" } } }, "localname": "FinancingFromFollowOnPublicOfferingNetOfIssuanceCost", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_FollowOnExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Follow on expenses.", "label": "Follow On Expenses", "terseLabel": "Follow-on expenses" } } }, "localname": "FollowOnExpenses", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "monetaryItemType" }, "legn_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on public offering.", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow-On Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "legn_FormerEmployeeDamagesDemand": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Former employee damages demand.", "label": "Former Employee Damages Demand", "terseLabel": "Former employee damages demand" } } }, "localname": "FormerEmployeeDamagesDemand", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_FreeholdLandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Freehold land.", "label": "Freehold Land [Member]", "terseLabel": "Freehold Land" } } }, "localname": "FreeholdLandMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptBiotechCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript Biotech Corporation.", "label": "Genscript Biotech Corporation [Member]", "terseLabel": "Genscript Biotech Corporation" } } }, "localname": "GenscriptBiotechCorporationMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptBiotechNetherlandsBVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript Biotech (Netherlands) B.V.", "label": "Genscript Biotech Netherlands B V [Member]", "terseLabel": "Genscript Biotech (Netherlands) B.V." } } }, "localname": "GenscriptBiotechNetherlandsBVMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript Group.", "label": "Genscript Group [Member]", "terseLabel": "Genscript Group" } } }, "localname": "GenscriptGroupMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptHongKongLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript (HongKong) Ltd.", "label": "Genscript Hong Kong Ltd [Member]", "terseLabel": "Genscript (HongKong) Ltd." } } }, "localname": "GenscriptHongKongLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptNanjingCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript (Nanjing) Co., Ltd.", "label": "Genscript Nanjing Co Ltd [Member]", "terseLabel": "Genscript (Nanjing) Co., Ltd. (formerly named as Jinsikang Technology (Nanjing) Co., Ltd.)", "verboseLabel": "Genscript (Nanjing) Co., Ltd." } } }, "localname": "GenscriptNanjingCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptNetherlandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript Netherlands.", "label": "Genscript Netherlands [Member]", "terseLabel": "Genscript Netherlands" } } }, "localname": "GenscriptNetherlandsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptUSAHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript USA Holdings Inc.", "label": "Genscript U S A Holdings Inc [Member]", "terseLabel": "Genscript USA Holdings Inc" } } }, "localname": "GenscriptUSAHoldingsIncMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GenscriptUSAIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genscript USA Incorporated.", "label": "Genscript U S A Incorporated [Member]", "terseLabel": "Genscript USA Incorporated" } } }, "localname": "GenscriptUSAIncorporatedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_GovernmentGrantAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government grant.", "label": "Government Grant [Abstract]" } } }, "localname": "GovernmentGrantAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_GovernmentGrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government grants.", "label": "Government Grants [Abstract]" } } }, "localname": "GovernmentGrantsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_GovernmentGrantsReceivedFromLocalGovernmentAuthorities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10070.0, "parentTag": "us-gaap_OtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Government grants received from local government authorities.", "label": "Government Grants Received From Local Government Authorities", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrantsReceivedFromLocalGovernmentAuthorities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "legn_HainanChuanjiBiotechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hainan Chuanji Biotechnology Co., Ltd.", "label": "Hainan Chuanji Biotechnology Co Ltd [Member]", "terseLabel": "Hainan Chuanji Biotechnology Co., Ltd. (\u201cHainan Chuanji\u201d)" } } }, "localname": "HainanChuanjiBiotechnologyCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_IncomeTaxRefundReceivable": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": 10030.0, "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax refund receivable.", "label": "Income Tax Refund Receivable", "terseLabel": "Income tax refund" } } }, "localname": "IncomeTaxRefundReceivable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseInContractLiabilities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10440.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in contract liabilities.", "label": "Increase Decrease In Contract Liabilities", "terseLabel": "(Decrease)/increase in contract liabilities" } } }, "localname": "IncreaseDecreaseInContractLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseInPledgedDepositsNet": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10450.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in pledged deposits net.", "label": "Increase Decrease In Pledged Deposits Net", "terseLabel": "Increase in pledged deposits, net" } } }, "localname": "IncreaseDecreaseInPledgedDepositsNet", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseOfConversionToOrdinaryShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) of conversion to ordinary shares.", "label": "Increase Decrease Of Conversion To Ordinary Shares", "negatedLabel": "Conversion to ordinary shares" } } }, "localname": "IncreaseDecreaseOfConversionToOrdinaryShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseThroughDisposalLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through disposal, liabilities arising from financing activities.", "label": "Increase Decrease Through Disposal Liabilities Arising From Financing Activities", "terseLabel": "Disposal" } } }, "localname": "IncreaseDecreaseThroughDisposalLiabilitiesArisingFromFinancingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through effect of exchange realignment in foreign exchange rate.", "label": "Increase Decrease Through Effect Of Exchange Realignment In Foreign Exchange Rate", "terseLabel": "Exchange realignment" } } }, "localname": "IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through reclassification of vested restricted stock, equity.", "label": "Increase Decrease Through Reclassification Of Vested Restricted Stock Equity", "terseLabel": "Reclassification of vested restricted stock units" } } }, "localname": "IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseInLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in lease liabilities.", "label": "Increase In Lease Liabilities", "terseLabel": "Increase" } } }, "localname": "IncreaseInLeaseLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseOfLeaseLiabilitiesBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase of lease liabilities balance.", "label": "Increase Of Lease Liabilities Balance", "terseLabel": "Accretion of interest recognized during the year" } } }, "localname": "IncreaseOfLeaseLiabilitiesBalance", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "monetaryItemType" }, "legn_IncreaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase right of use assets.", "label": "Increase Right Of Use Assets", "terseLabel": "Increase" } } }, "localname": "IncreaseRightOfUseAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "monetaryItemType" }, "legn_InitialPublicOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial public offering expenses", "label": "Initial Public Offering Expenses", "terseLabel": "IPO expenses" } } }, "localname": "InitialPublicOfferingExpenses", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "monetaryItemType" }, "legn_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "legn_InterestBearingBorrowingsFundedInterestsAccrued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest bearing borrowings funded interests accrued.", "label": "Interest Bearing Borrowings Funded Interests Accrued", "terseLabel": "Interest bearing borrowings funded interests accrued" } } }, "localname": "InterestBearingBorrowingsFundedInterestsAccrued", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_InterestBearingLoanAndBorrowings": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": 10040.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest-bearing loans and borrowings.", "label": "Interest Bearing Loan And Borrowings", "terseLabel": "Interest-bearing loans and borrowings (note)" } } }, "localname": "InterestBearingLoanAndBorrowings", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "legn_InterestBearingLoanAndBorrowingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest bearing loan and borrowings member.", "label": "Interest Bearing Loan And Borrowings [Member]", "terseLabel": "Interest Bearing Loan And Borrowings" } } }, "localname": "InterestBearingLoanAndBorrowingsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10340.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest on lease payments classified as operating activities.", "label": "Interest On Lease Payments Classified As Operating Activities", "terseLabel": "Interest on lease payments" } } }, "localname": "InterestOnLeasePaymentsClassifiedAsOperatingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_InterestOnLoanFromRelatedPartyClassifiedAsOperatingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10320.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest on loan from related party classified as operating activities.", "label": "Interest On Loan From Related Party Classified As Operating Activities", "terseLabel": "Interest on loan from related party" } } }, "localname": "InterestOnLoanFromRelatedPartyClassifiedAsOperatingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_IssuanceOfOrdinaryShareRelatingToPrivatePlacementForInstitutionalInvestor": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares relating to private placement for institutional investor.", "label": "Issuance Of Ordinary Share Relating To Private Placement For Institutional Investor", "terseLabel": "Issuance of ordinary shares relating to private placement for an institutional investor" } } }, "localname": "IssuanceOfOrdinaryShareRelatingToPrivatePlacementForInstitutionalInvestor", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "legn_IssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares and warrant relating to private placement for institutional investor.", "label": "Issuance Of Ordinary Shares And Warrant Relating To Private Placement For Institutional Investor Number Of Shares Issue", "terseLabel": "Issuance of ordinary shares and warrant relating to private placement for an institutional investor" } } }, "localname": "IssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_IssuanceOfOrdinarySharesForConversionOfPreferredShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for conversion of preferred shares.", "label": "Issuance Of Ordinary Shares For Conversion Of Preferred Shares", "terseLabel": "Issuance of ordinary shares for conversion of preferred shares" } } }, "localname": "IssuanceOfOrdinarySharesForConversionOfPreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_IssuanceOfOrdinarySharesForConversionOfPreferredSharesNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for conversion of preferred shares, number of shares in issue.", "label": "Issuance Of Ordinary Shares For Conversion Of Preferred Shares Number Of Shares In Issue", "terseLabel": "Issuance of ordinary shares for conversion of preferred shares" } } }, "localname": "IssuanceOfOrdinarySharesForConversionOfPreferredSharesNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for follow-on-public offering, net of issuance cost, number of shares in issue.", "label": "Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Cost Number Of Shares In Issue", "terseLabel": "Issuance of ordinary shares for follow-on public offering,net of issuance cost (note)" } } }, "localname": "IssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_IssuanceOfOrdinarySharesForInitialPublicOfferingNetOfIssuanceCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for initial public offering, net of issuance cost.", "label": "Issuance Of Ordinary Shares For Initial Public Offering Net Of Issuance Cost", "terseLabel": "Issuance of ordinary shares for initial public offering, net of issuance cost" } } }, "localname": "IssuanceOfOrdinarySharesForInitialPublicOfferingNetOfIssuanceCost", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_IssuanceOfOrdinarySharesForInitialPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for initial public offering, net of issuance cost, number of shares in issue.", "label": "Issuance Of Ordinary Shares For Initial Public Offering Net Of Issuance Cost Number Of Shares In Issue", "terseLabel": "Issuance of ordinary shares for initial public offering, net of issuance cost" } } }, "localname": "IssuanceOfOrdinarySharesForInitialPublicOfferingNetOfIssuanceCostNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_IssuanceOfOrdinarySharesForPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for private placement.", "label": "Issuance Of Ordinary Shares For Private Placement", "terseLabel": "Issuance of ordinary shares for private placement by GenScript" } } }, "localname": "IssuanceOfOrdinarySharesForPrivatePlacement", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_IssuanceOfOrdinarySharesForPrivatePlacementNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares for private placement, number of shares in issue.", "label": "Issuance Of Ordinary Shares For Private Placement Number Of Shares In Issue", "terseLabel": "Issuance of ordinary shares for private placement by GenScript" } } }, "localname": "IssuanceOfOrdinarySharesForPrivatePlacementNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_IssuanceOfOrdinarySharesRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares relating to private placement for institutional investor number of shares issue.", "label": "Issuance Of Ordinary Shares Relating To Private Placement For Institutional Investor Number Of Shares Issue", "terseLabel": "Issuance of ordinary shares relating to private placement for an institutional investor (note 24)" } } }, "localname": "IssuanceOfOrdinarySharesRelatingToPrivatePlacementForInstitutionalInvestorNumberOfSharesIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_JSCServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "JSC service.", "label": "J S C Service [Member]", "terseLabel": "JSC service" } } }, "localname": "JSCServiceMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfDetailsOfContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "legn_JiangsuGenscriptBiotechCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jiangsu Genscript Biotech Co., Ltd.", "label": "Jiangsu Genscript Biotech Co Ltd [Member]", "terseLabel": "Jiangsu GenScript Biotech Co., Ltd" } } }, "localname": "JiangsuGenscriptBiotechCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_JiangsuGenscriptProbioBiotechCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jiangsu Genscript Probio Biotech Co., Ltd.", "label": "Jiangsu Genscript Probio Biotech Co Ltd [Member]", "terseLabel": "Jiangsu GenScript Probio Biotech Co., Ltd." } } }, "localname": "JiangsuGenscriptProbioBiotechCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_JinsikangTechnologyNanjingCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jinsikang Technology (Nanjing) Co., Ltd.", "label": "Jinsikang Technology Nanjing Co Ltd [Member]", "terseLabel": "Jinsikang Technology Nanjing Co Ltd" } } }, "localname": "JinsikangTechnologyNanjingCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_JointSteeringCommitteeServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joint steering committee service.", "label": "Joint Steering Committee Service [Member]", "terseLabel": "JSC service" } } }, "localname": "JointSteeringCommitteeServiceMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "domainItemType" }, "legn_LaterThanFourYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Later than four years.", "label": "Later Than Four Years [Member]", "terseLabel": "After 4 years" } } }, "localname": "LaterThanFourYearsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAmountsOfTransactionPricesAllocatedToRemainingPerformanceObligationsUnsatisfiedOrPartiallyUnsatisfiedDetails" ], "xbrltype": "domainItemType" }, "legn_LeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease abstract.", "label": "Lease [Abstract]" } } }, "localname": "LeaseAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_LeaseExpenseAmountRecognizedInProfitOrLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease expense amount recognized in profit or loss.", "label": "Lease Expense Amount Recognized In Profit Or Loss", "terseLabel": "Total amount recognized in profit or loss" } } }, "localname": "LeaseExpenseAmountRecognizedInProfitOrLoss", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "legn_LeaseLiabilitiesDisposal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities, disposal.", "label": "Lease Liabilities Disposal", "terseLabel": "Disposal" } } }, "localname": "LeaseLiabilitiesDisposal", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "monetaryItemType" }, "legn_LeaseLiabilitiesLeaseModifications": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities lease modifications.", "label": "Lease Liabilities Lease Modifications", "terseLabel": "Lease modification" } } }, "localname": "LeaseLiabilitiesLeaseModifications", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseLiabilitiesMeasuredAtPresentValueOfLeasePaymentsToBeMadeOverLeaseTermDetails" ], "xbrltype": "monetaryItemType" }, "legn_LeaseLiabilitiesRepaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease liabilities, repayment term.", "label": "Lease Liabilities Repayment Term", "terseLabel": "Lease liabilities, repayment term" } } }, "localname": "LeaseLiabilitiesRepaymentTerm", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_LeaseModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease modification.", "label": "Lease Modification", "terseLabel": "Lease modification" } } }, "localname": "LeaseModification", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "monetaryItemType" }, "legn_LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease terms and estimated useful lives of right of use assets.", "label": "Lease Terms And Estimated Useful Lives Of Right Of Use Assets", "terseLabel": "Lease terms and estimated useful lives of right-of-use assets" } } }, "localname": "LeaseTermsAndEstimatedUsefulLivesOfRightOfUseAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "legn_LeaseholdLandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leasehold land.", "label": "Leasehold Land [Member]", "terseLabel": "Leasehold Land" } } }, "localname": "LeaseholdLandMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRightOfUseAssetsDepreciatedOnStraightLineBasisOverLeaseTermsAndEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "legn_LeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases line items.", "label": "Leases [Line Items]", "terseLabel": "Leases [Line Items]" } } }, "localname": "LeasesLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_LeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases table.", "label": "Leases [Table]", "terseLabel": "Leases [Table]" } } }, "localname": "LeasesTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_LegendBiotechBelgiumBVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Biotech Belgium B.V.", "label": "Legend Biotech Belgium B V [Member]", "terseLabel": "Legend Biotech Belgium B.V. (\u201cLegend Belgium\u201d)" } } }, "localname": "LegendBiotechBelgiumBVMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_LegendBiotechHKLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Biotech HK Limited.", "label": "Legend Biotech H K Limited [Member]", "terseLabel": "Legend Biotech HK Limited (\u201cLegend HK\u201d)" } } }, "localname": "LegendBiotechHKLimitedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_LegendBiotechIrelandLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Biotech Ireland Limited.", "label": "Legend Biotech Ireland Limited [Member]", "terseLabel": "Legend Biotech Ireland Limited. (\"Legend Ireland\")" } } }, "localname": "LegendBiotechIrelandLimitedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_LegendBiotechLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Biotech Limited.", "label": "Legend Biotech Limited [Member]", "terseLabel": "Legend Biotech Limited (\"Legend BVI\")" } } }, "localname": "LegendBiotechLimitedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_LegendBiotechUSAIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Biotech USA Incorporated.", "label": "Legend Biotech U S A Incorporated [Member]", "terseLabel": "Legend Biotech USA Incorporated (\u201cLegend USA\u201d)" } } }, "localname": "LegendBiotechUSAIncorporatedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_LegendIrelandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legend Ireland", "label": "Legend Ireland [Member]", "terseLabel": "Legend Ireland" } } }, "localname": "LegendIrelandMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_LesseeLeaseExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee lease expenses text block.", "label": "Lessee Lease Expenses [Text Block]", "terseLabel": "Summary of Lease Expense" } } }, "localname": "LesseeLeaseExpensesTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "legn_LesseeLeaseLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee lease liabilities text block.", "label": "Lessee Lease Liabilities [Text Block]", "terseLabel": "Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term" } } }, "localname": "LesseeLeaseLiabilitiesTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "legn_LesseeLeasingArrangementsLeasesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee leasing arrangements leases term.", "label": "Lessee Leasing Arrangements Leases Term", "terseLabel": "Lessee, lease terms" } } }, "localname": "LesseeLeasingArrangementsLeasesTerm", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_LesseeLeasingArrangementsLeasesTermDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee leasing arrangements leases term description.", "label": "Lessee Leasing Arrangements Leases Term Description", "terseLabel": "Lessee, lease term description" } } }, "localname": "LesseeLeasingArrangementsLeasesTermDescription", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_LesseesIncrementalBorrowingRateAppliedToLeaseLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessees incremental borrowing rate applied to lease liabilities.", "label": "Lessees Incremental Borrowing Rate Applied To Lease Liabilities", "terseLabel": "Lessee's incremental borrowing rate applied to lease liabilities" } } }, "localname": "LesseesIncrementalBorrowingRateAppliedToLeaseLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_LessorLeasingArrangementLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor leasing arrangement lease term.", "label": "Lessor Leasing Arrangement Lease Term", "terseLabel": "Lease term" } } }, "localname": "LessorLeasingArrangementLeaseTerm", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_LicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreement.", "label": "License And Collaboration Agreement [Member]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "LicenseAndCollaborationAgreementMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_LicensingOfIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing of intellectual property.", "label": "Licensing Of Intellectual Property [Member]", "terseLabel": "Licensing of intellectual property" } } }, "localname": "LicensingOfIntellectualPropertyMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails" ], "xbrltype": "domainItemType" }, "legn_MajorComponentsOfTaxExpenseIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Major components of tax expense income.", "label": "Major Components Of Tax Expense Income [Line Items]", "terseLabel": "Major Components Of Tax Expense Income [Line Items]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "stringItemType" }, "legn_MajorComponentsOfTaxExpenseIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Major components of tax expense income.", "label": "Major Components Of Tax Expense Income [Table]", "terseLabel": "Major Components Of Tax Expense Income [Table]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "stringItemType" }, "legn_ManagementFeeRelatedPartyTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Management fee, related party transactions.", "label": "Management Fee Related Party Transactions", "terseLabel": "Management fee" } } }, "localname": "ManagementFeeRelatedPartyTransactions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_MilestoneAchievementClinicalMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone achievement clinical milestone.", "label": "Milestone Achievement Clinical Milestone", "terseLabel": "Milestone achievement, clinical milestone" } } }, "localname": "MilestoneAchievementClinicalMilestone", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_MilestonePaymentNotEligibleToReceiveBasedOnSubsequentChangeInDevelopmentPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment not eligible to receive based on subsequent change in development plan.", "label": "Milestone Payment Not Eligible To Receive Based On Subsequent Change In Development Plan", "terseLabel": "Milestone payment not eligible to receive based on subsequent change in development plan" } } }, "localname": "MilestonePaymentNotEligibleToReceiveBasedOnSubsequentChangeInDevelopmentPlan", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_MilestonePaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment receivable.", "label": "Milestone Payment Receivable", "terseLabel": "Milestone payment receivable" } } }, "localname": "MilestonePaymentReceivable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NanjingBestzymeBioengineeringCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nanjing Bestzyme Bioengineering Co., Ltd.", "label": "Nanjing Bestzyme Bioengineering Co Ltd [Member]", "terseLabel": "Nanjing Bestzyme Bioengineering Co., Ltd." } } }, "localname": "NanjingBestzymeBioengineeringCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails" ], "xbrltype": "domainItemType" }, "legn_NanjingGenScriptBiotechCoLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nanjing GenScript Biotech Co., Ltd.", "label": "Nanjing Gen Script Biotech Co Limited [Member]", "terseLabel": "Nanjing GenScript Biotech Co., Ltd" } } }, "localname": "NanjingGenScriptBiotechCoLimitedMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_NanjingLegendBiotechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nanjing Legend Biotechnology Co Ltd.", "label": "Nanjing Legend Biotechnology Co Ltd [Member]", "terseLabel": "Nanjing Legend Biotechnology Co.,Ltd. (\u201cLegend Nanjing\u201d)" } } }, "localname": "NanjingLegendBiotechnologyCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "legn_NanjingProbioBiotechCoLtdAndJiangsuGenScriptProbioBiotechCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nanjing Probio Biotech Co., Ltd. and Jiangsu GenScript Probio Biotech Co., Ltd.", "label": "Nanjing Probio Biotech Co Ltd And Jiangsu Gen Script Probio Biotech Co Ltd [Member]", "terseLabel": "Nanjing Probio Biotech Co., Ltd. and Jiangsu GenScript Probio Biotech Co., Ltd." } } }, "localname": "NanjingProbioBiotechCoLtdAndJiangsuGenScriptProbioBiotechCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_NanjingProbioBiotechCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nanjing Probio Biotech Co Ltd.", "label": "Nanjing Probio Biotech Co Ltd [Member]", "terseLabel": "Nanjing Probio Biotech Co., Ltd." } } }, "localname": "NanjingProbioBiotechCoLtdMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfNatureOfRelatedPartyRelationshipDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_NonCashAdditionToInterestBearingLoansAndBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash addition to interest-bearing loans and borrowings.", "label": "Non Cash Addition To Interest Bearing Loans And Borrowings", "terseLabel": "Non cash additions to interest-bearing loans and borrowings" } } }, "localname": "NonCashAdditionToInterestBearingLoansAndBorrowings", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashAdditionsToFinanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash additions to finance costs.", "label": "Non Cash Additions To Finance Costs", "terseLabel": "Non-cash additions to finance costs" } } }, "localname": "NonCashAdditionsToFinanceCosts", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashAdditionsToLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash additions to lease liabilities.", "label": "Non Cash Additions To Lease Liabilities", "terseLabel": "Non-cash additions to lease liabilities" } } }, "localname": "NonCashAdditionsToLeaseLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashAdditionsToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash additions to property, plant and equipment.", "label": "Non Cash Additions To Property Plant And Equipment", "terseLabel": "Non-cash additions to property, plant and equipment" } } }, "localname": "NonCashAdditionsToPropertyPlantAndEquipment", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashAdditionsToRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash additions to right-of-use assets.", "label": "Non Cash Additions To Right Of Use Assets", "terseLabel": "Non-cash additions to right-of-use assets" } } }, "localname": "NonCashAdditionsToRightOfUseAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashFairValueLossOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash fair value loss of warrant liability.", "label": "Non Cash Fair Value Loss Of Warrant Liability", "terseLabel": "Non cash fair value loss of warrant liability" } } }, "localname": "NonCashFairValueLossOfWarrantLiability", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashOtherPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash other payable.", "label": "Non Cash Other Payable", "terseLabel": "Non-cash other payable" } } }, "localname": "NonCashOtherPayable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashPrepaymentInExchangeOfResearchAndDevelopmentService": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash prepayment in exchange of research and development service.", "label": "Non Cash Prepayment In Exchange Of Research And Development Service", "terseLabel": "Non-cash prepayment in exchange of research and development service" } } }, "localname": "NonCashPrepaymentInExchangeOfResearchAndDevelopmentService", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonCashTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash transaction.", "label": "Non Cash Transaction", "negatedLabel": "Non-cash transaction" } } }, "localname": "NonCashTransaction", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonRefundableUpfrontAmountRecognizedAsRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront amount recognized as revenue.", "label": "Non Refundable Upfront Amount Recognized As Revenue", "terseLabel": "Non-refundable upfront amount recognized as revenue" } } }, "localname": "NonRefundableUpfrontAmountRecognizedAsRevenue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_NonTradingIncomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non trading income tax rate.", "label": "Non Trading Income Tax Rate", "terseLabel": "Non trading income tax rate" } } }, "localname": "NonTradingIncomeTaxRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_NonUSTerritoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-U.S. territories.", "label": "Non U S Territories [Member]", "terseLabel": "Non-U.S. territories" } } }, "localname": "NonUSTerritoriesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_NotesPayables": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails": { "order": 10020.0, "parentTag": "legn_TradeAndNotesPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payables.", "label": "Notes Payables", "terseLabel": "Notes payable" } } }, "localname": "NotesPayables", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails" ], "xbrltype": "monetaryItemType" }, "legn_NumberOfAdditionalMilestonePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional milestone payments.", "label": "Number Of Additional Milestone Payments", "terseLabel": "Number of additional milestone payments" } } }, "localname": "NumberOfAdditionalMilestonePayments", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "legn_NumberOfCarParkingSpaces": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of car parking spaces.", "label": "Number Of Car Parking Spaces", "terseLabel": "Number of car parking spaces" } } }, "localname": "NumberOfCarParkingSpaces", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "legn_NumberOfMilestonePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestone payments.", "label": "Number Of Milestone Payments", "terseLabel": "Number of milestone payments" } } }, "localname": "NumberOfMilestonePayments", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "legn_OngoingLeasePaymentsUnderTheLandLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Ongoing lease payments under the land lease.", "label": "Ongoing Lease Payments Under The Land Lease", "terseLabel": "Ongoing lease payments" } } }, "localname": "OngoingLeasePaymentsUnderTheLandLease", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other countries.", "label": "Other Countries [Member]", "terseLabel": "Others" } } }, "localname": "OtherCountriesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_OtherFinanceGains": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10050.0, "parentTag": "ifrs-full_OtherGainsLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other finance gains.", "label": "Other Finance Gains", "terseLabel": "Others" } } }, "localname": "OtherFinanceGains", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "legn_OtherIncomeAndGains": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other income and gains.", "label": "Other Income And Gains", "totalLabel": "Other Income And Gains" } } }, "localname": "OtherIncomeAndGains", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "legn_OtherIncomeAndGainsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income and gains.", "label": "Other Income And Gains [Abstract]", "terseLabel": "Other income and gains" } } }, "localname": "OtherIncomeAndGainsAbstract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "stringItemType" }, "legn_OtherIncomeRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other income related party transactions.", "label": "Other Income Related Party Transactions", "terseLabel": "Other income to related parties" } } }, "localname": "OtherIncomeRelatedPartyTransactions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_OtherPayablesAndAccrualsCurrent": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "order": 10020.0, "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0 }, "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10130.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other payables and accruals, current.", "label": "Other Payables And Accruals Current", "terseLabel": "Other payables and accruals", "totalLabel": "Other payables and accruals" } } }, "localname": "OtherPayablesAndAccrualsCurrent", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfMaturityProfileOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_OtherPayablesAndAccrualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables and accruals.", "label": "Other Payables And Accruals [Member]", "terseLabel": "Other Payables and Accruals" } } }, "localname": "OtherPayablesAndAccrualsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other Payables [Member]", "terseLabel": "Other Payables" } } }, "localname": "OtherPayablesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_OtherPayablesToRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables to related parties.", "label": "Other Payables To Related Parties [Member]", "terseLabel": "Other Payables to Related Parties" } } }, "localname": "OtherPayablesToRelatedPartiesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureNotesToConsolidatedStatementOfCashFlowsSummaryOfChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "xbrltype": "domainItemType" }, "legn_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables.", "label": "Other Receivables [Member]", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_OtherTaxPayables": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails": { "order": 10040.0, "parentTag": "legn_OtherPayablesAndAccrualsCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other tax payables,", "label": "Other Tax Payables", "terseLabel": "Other tax payables" } } }, "localname": "OtherTaxPayables", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOtherPayablesAndAccrualsSummaryOfOtherPayablesAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "legn_OtherThanUSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other than U.S.", "label": "Other Than U S [Member]", "terseLabel": "Elsewhere" } } }, "localname": "OtherThanUSMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfTaxChargesDetails" ], "xbrltype": "domainItemType" }, "legn_OutstandingForeignCurrencyForwardExchangeContracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Outstanding foreign currency forward exchange contracts.", "label": "Outstanding Foreign Currency Forward Exchange Contracts", "terseLabel": "Outstanding foreign currency forward exchange contracts" } } }, "localname": "OutstandingForeignCurrencyForwardExchangeContracts", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_PaidInCapitalAndReserveFunds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Paid in capital and reserve funds.", "label": "Paid In Capital And Reserve Funds", "terseLabel": "Paid in capital and reserve funds" } } }, "localname": "PaidInCapitalAndReserveFunds", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureReservesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_PaymentsOfExpensesForIssuanceOfConvertibleRedeemablePreferredShares": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10140.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of expenses for issuance of convertible redeemable preferred shares.", "label": "Payments Of Expenses For Issuance Of Convertible Redeemable Preferred Shares", "negatedLabel": "Payments of expenses for issuance of convertible redeemable preferred shares" } } }, "localname": "PaymentsOfExpensesForIssuanceOfConvertibleRedeemablePreferredShares", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_PercentageOfConcentrationOfCreditRiskOfTradeReceivablesDueFromOneSingleCustomerUnderLicenseAndCollaborationAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of concentration of credit risk of trade receivables due from one single customer under license and collaboration agreement.", "label": "Percentage Of Concentration Of Credit Risk Of Trade Receivables Due From One Single Customer Under License And Collaboration Agreement", "terseLabel": "Percentage of concentration of credit risk of trade receivables due from one single customer under a license and collaboration agreement" } } }, "localname": "PercentageOfConcentrationOfCreditRiskOfTradeReceivablesDueFromOneSingleCustomerUnderLicenseAndCollaborationAgreement", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_PercentageOfDividends": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of dividends.", "label": "Percentage Of Dividends", "terseLabel": "Percentage of dividends" } } }, "localname": "PercentageOfDividends", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_PercentageOfForeignCurrencyForwardExchangeContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of foreign currency forward exchange contract.", "label": "Percentage Of Foreign Currency Forward Exchange Contract", "terseLabel": "Percentage of foreign currency forward exchange contract" } } }, "localname": "PercentageOfForeignCurrencyForwardExchangeContract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_PercentageOfIncreaseDecreaseInRateOfForeignCurrency": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase (decrease) in the rate of foreign currency.", "label": "Percentage Of Increase Decrease In Rate Of Foreign Currency", "terseLabel": "Increase/ (decrease) in the rate of foreign currency" } } }, "localname": "PercentageOfIncreaseDecreaseInRateOfForeignCurrency", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "percentItemType" }, "legn_PercentageOfNumberOfNumberSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of number of number shares issued.", "label": "Percentage Of Number Of Number Shares Issued", "terseLabel": "Percentage of number of number shares issued" } } }, "localname": "PercentageOfNumberOfNumberSharesIssued", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_PercentageOfOutstandingShareOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding share options.", "label": "Percentage Of Outstanding Share Options", "terseLabel": "Percentage of options outstanding" } } }, "localname": "PercentageOfOutstandingShareOptions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_PerformanceObligationsEstimatedCollaborationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance obligations estimated collaboration period", "label": "Performance Obligations Estimated Collaboration Period", "terseLabel": "Performance obligations estimated collaboration period" } } }, "localname": "PerformanceObligationsEstimatedCollaborationPeriod", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_PeriodOfShareOptionSchemeRemainInForce": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of share option scheme remain in force.", "label": "Period Of Share Option Scheme Remain In Force", "terseLabel": "Period of share option scheme remain in force" } } }, "localname": "PeriodOfShareOptionSchemeRemainInForce", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_PlaceAndDateOfIncorporationLiquidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Place and date of incorporation/liquidation.", "label": "Place And Date Of Incorporation Liquidation", "terseLabel": "Place and date of incorporation/liquidation" } } }, "localname": "PlaceAndDateOfIncorporationLiquidation", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "legn_PlaceAndDateOfIncorporationOfBusinessOfSubsidiary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Place and date of incorporation of business of subsidiary.", "label": "Place And Date Of Incorporation Of Business Of Subsidiary", "terseLabel": "Place and date of incorporation" } } }, "localname": "PlaceAndDateOfIncorporationOfBusinessOfSubsidiary", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCorporateInformationInformationAboutSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "legn_PledgedDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10240.0, "parentTag": "ifrs-full_CurrentAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pledged deposits.", "label": "Pledged Deposits", "negatedLabel": "Pledged deposits" } } }, "localname": "PledgedDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_PledgedDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pledged deposits.", "label": "Pledged Deposits [Member]", "terseLabel": "Pledged Deposits" } } }, "localname": "PledgedDepositsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_PledgedShortTermDeposits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pledged short-term deposits.", "label": "Pledged Short Term Deposits", "terseLabel": "Less: Pledged deposits" } } }, "localname": "PledgedShortTermDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "monetaryItemType" }, "legn_PrepaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment.", "label": "Prepayment [Member]", "terseLabel": "Prepayment" } } }, "localname": "PrepaymentMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_PrepaymentsOtherReceivablesAndOtherAssets": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayments, other receivables and other assets.", "label": "Prepayments Other Receivables And Other Assets", "totalLabel": "Total" } } }, "localname": "PrepaymentsOtherReceivablesAndOtherAssets", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "legn_PrepaymentsOtherReceivablesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayments other receivables and other assets.,", "label": "Prepayments Other Receivables And Other Assets [Member]", "terseLabel": "Prepayments Other Receivable and Other Assets" } } }, "localname": "PrepaymentsOtherReceivablesAndOtherAssetsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosurePrepaymentsOtherReceivablesAndOtherAssetsSummaryOfPrepaymentsOtherReceivablesAndOtherAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_PrivatePlacementByGenscriptMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement by GenScript.", "label": "Private Placement By Genscript [Member]", "terseLabel": "Private Placement by Genscript" } } }, "localname": "PrivatePlacementByGenscriptMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "legn_ProceedsFromIssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForAnInstitutionalInvestor": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10120.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor.", "label": "Proceeds From Issuance Of Ordinary Shares And Warrant Relating To Private Placement For An Institutional Investor", "terseLabel": "Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor" } } }, "localname": "ProceedsFromIssuanceOfOrdinarySharesAndWarrantRelatingToPrivatePlacementForAnInstitutionalInvestor", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_ProceedsFromIssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10110.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs.", "label": "Proceeds From Issuance Of Ordinary Shares For Follow On Public Offering Net Of Issuance Costs", "terseLabel": "Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfOrdinarySharesForFollowOnPublicOfferingNetOfIssuanceCosts", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_ProceedsFromIssuanceOfOrdinarySharesRelatingToPrivatePlacement": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10100.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of ordinary shares relating to private placement.", "label": "Proceeds From Issuance Of Ordinary Shares Relating To Private Placement", "terseLabel": "Proceeds from issuance of ordinary shares relating to private placement by GenScript" } } }, "localname": "ProceedsFromIssuanceOfOrdinarySharesRelatingToPrivatePlacement", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_ProfitLossBeforeTaxArrivedAfterChargingAndCreditingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit loss before tax arrived after charging and crediting.", "label": "Profit Loss Before Tax Arrived After Charging And Crediting [Member]", "terseLabel": "Profit Loss Before Tax Arrived After Charging And Crediting" } } }, "localname": "ProfitLossBeforeTaxArrivedAfterChargingAndCreditingMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "domainItemType" }, "legn_ProfitLossBeforeTaxExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for profit loss before tax.", "label": "Profit Loss Before Tax Explanatory", "terseLabel": "Loss Before Tax" } } }, "localname": "ProfitLossBeforeTaxExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTax" ], "xbrltype": "textBlockItemType" }, "legn_ProfitLossBeforeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent profit loss before tax.", "label": "Profit Loss Before Tax [Line Items]", "terseLabel": "Profit Loss Before Tax [Line Items]" } } }, "localname": "ProfitLossBeforeTaxLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "stringItemType" }, "legn_ProfitLossBeforeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to profit loss before tax.", "label": "Profit Loss Before Tax [Table]", "terseLabel": "Profit Loss Before Tax [Table]" } } }, "localname": "ProfitLossBeforeTaxTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLossBeforeTaxSummeryOfLossBeforeTaxIsArrivedAtAfterChargingCreditingDetail" ], "xbrltype": "stringItemType" }, "legn_PropertyLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property lease agreement.", "label": "Property Lease Agreement [Member]", "terseLabel": "Property Lease Agreement" } } }, "localname": "PropertyLeaseAgreementMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_ProvisionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provisions", "label": "Provisions Policy [Text Block]", "terseLabel": "Provisions" } } }, "localname": "ProvisionsPolicyTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10180.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets at fair value through profit or loss classified as investing activities.", "label": "Purchase Of Financial Assets At Fair Value Through Profit Or Loss Classified As Investing Activities", "negatedLabel": "Purchase of financial assets measured at fair value through profit or loss" } } }, "localname": "PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_PurchaseOfFinancialAssetsMeasuredAtAmortizedCost": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10280.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets measured at amortized cost.", "label": "Purchase Of Financial Assets Measured At Amortized Cost", "negatedLabel": "Purchase of financial assets measured at amortized cost" } } }, "localname": "PurchaseOfFinancialAssetsMeasuredAtAmortizedCost", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassification of vested restricted stock units, number of shares in issue.", "label": "Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue", "terseLabel": "Reclassification of vesting of restricted stock units" } } }, "localname": "ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of vested restricted stock units, share capital and share premium.", "label": "Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium", "terseLabel": "Reclassification of vesting of restricted stockunits" } } }, "localname": "ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_ReconciliationOfChangesInDeferredTaxAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of changes in deferred tax assets.", "label": "Reconciliation Of Changes In Deferred Tax Assets [Line Items]", "terseLabel": "Reconciliation of Changes in Deferred Tax Assets [Line Items]" } } }, "localname": "ReconciliationOfChangesInDeferredTaxAssetsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_ReconciliationOfChangesInDeferredTaxAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of changes in deferred tax assets table.", "label": "Reconciliation Of Changes In Deferred Tax Assets [Table]", "terseLabel": "Reconciliation Of Changes In Deferred Tax Assets [Table]" } } }, "localname": "ReconciliationOfChangesInDeferredTaxAssetsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_RepaymentsOfEntrustedLoanFromRelatedPartyTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of entrusted loan from a related party transaction.", "label": "Repayments Of Entrusted Loan From Related Party Transaction", "terseLabel": "Repayments of entrusted loan from a related party" } } }, "localname": "RepaymentsOfEntrustedLoanFromRelatedPartyTransaction", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_RestrictedStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock plan.", "label": "Restricted Stock Plan [Member]", "terseLabel": "Restricted Share Plan" } } }, "localname": "RestrictedStockPlanMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_RestrictedStockUnitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units.", "label": "Restricted Stock Units [Abstract]" } } }, "localname": "RestrictedStockUnitsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_RestrictedStockUnitsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units.", "label": "Restricted Stock Units Explanatory", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnits" ], "xbrltype": "textBlockItemType" }, "legn_RestrictedStockUnitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units line items", "label": "Restricted Stock Units [Line Items]", "terseLabel": "Restricted Stock Units [Line Items]" } } }, "localname": "RestrictedStockUnitsLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "stringItemType" }, "legn_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units member.", "label": "Restricted Stock Units [Member]", "terseLabel": "RSU" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_RestrictedStockUnitsSchemeTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units scheme term.", "label": "Restricted Stock Units Scheme Term", "terseLabel": "Restricted stock units scheme term" } } }, "localname": "RestrictedStockUnitsSchemeTerm", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_RestrictedStockUnitsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units table.", "label": "Restricted Stock Units [Table]", "terseLabel": "Restricted Stock Units [Table]" } } }, "localname": "RestrictedStockUnitsTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRestrictedStockUnitsSummaryOfMovementInNumberOfRSUOutstandingDetails" ], "xbrltype": "stringItemType" }, "legn_RevenueFromJointSteeringCommitteeService": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails": { "order": 10030.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from joint steering committee service", "label": "Revenue From Joint Steering Committee Service", "terseLabel": "License and collaboration revenue" } } }, "localname": "RevenueFromJointSteeringCommitteeService", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "legn_RevenueFromLicenseAndCollaborationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from license and collaboration revenue.", "label": "Revenue From License And Collaboration Revenue [Abstract]", "terseLabel": "License and collaboration revenue" } } }, "localname": "RevenueFromLicenseAndCollaborationRevenueAbstract", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedFromPerformanceObligationSatisfiedInPreviousPeriodsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfRevenueRecognizedThatWasIncludedInContractLiabilitiesAtBeginningOfReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "legn_RevenueFromLicensingAndRoyalties": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails": { "order": 10040.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from licensing and royalties.", "label": "Revenue From Licensing And Royalties", "terseLabel": "Licensing and royalties" } } }, "localname": "RevenueFromLicensingAndRoyalties", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "legn_RevenueFromLicensingOfIntellectualProperty": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails": { "order": 10020.0, "parentTag": "ifrs-full_RevenueFromContractsWithCustomers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from licensing of intellectual property.", "label": "Revenue From Licensing Of Intellectual Property", "terseLabel": "License and collaboration revenue" } } }, "localname": "RevenueFromLicensingOfIntellectualProperty", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsSummaryOfAnalysisOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "legn_RevenueFromLicensingOfPatentsRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from licensing of patents related party transactions.", "label": "Revenue From Licensing Of Patents Related Party Transactions", "terseLabel": "Licensing of patents to related parties" } } }, "localname": "RevenueFromLicensingOfPatentsRelatedPartyTransactions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_RevenueFromSalesBasedRoyaltiesFromRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from sales-based royalties from related party transactions.", "label": "Revenue From Sales Based Royalties From Related Party Transactions", "terseLabel": "Sales-based royalties from related parties" } } }, "localname": "RevenueFromSalesBasedRoyaltiesFromRelatedPartyTransactions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "legn_RevenueOtherIncomeAndGainsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, other income and gains.", "label": "Revenue Other Income And Gains [Abstract]" } } }, "localname": "RevenueOtherIncomeAndGainsAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_RightOfUseAssetsDisposal": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right-of-use assets, disposal.", "label": "Right Of Use Assets Disposal", "terseLabel": "Disposal" } } }, "localname": "RightOfUseAssetsDisposal", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfCarryingAmountsOfTheRightOfUseAssetsAndMovementsDetails" ], "xbrltype": "monetaryItemType" }, "legn_RightToUseLicenseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-to-use license amount.", "label": "Right To Use License Amount", "terseLabel": "Right-to-use license amount" } } }, "localname": "RightToUseLicenseAmount", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_ScheduleOfContractLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of contract liabilities.", "label": "Schedule Of Contract Liabilities", "terseLabel": "Schedule of Details of Contract Liabilities" } } }, "localname": "ScheduleOfContractLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "legn_SellingAndDistributionExpenses": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": { "order": 10110.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling and distribution expenses.", "label": "Selling And Distribution Expenses", "negatedLabel": "Selling and distribution expenses" } } }, "localname": "SellingAndDistributionExpenses", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "legn_SeriesAConvertibleRedeemablePreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible redeemable preferred shares.", "label": "Series A Convertible Redeemable Preferred Shares [Member]", "terseLabel": "Series A Preference Shares" } } }, "localname": "SeriesAConvertibleRedeemablePreferredSharesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureConvertibleRedeemablePreferredSharesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_ShareCapitalAndSharePremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share capital and share premium.", "label": "Share Capital And Share Premium", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareCapitalAndSharePremium", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "monetaryItemType" }, "legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share capital and share premium, number of shares in issue.", "label": "Share Capital And Share Premium Number Of Shares In Issue", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareCapitalAndSharePremiumNumberOfSharesInIssue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "sharesItemType" }, "legn_ShareCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share capital.", "label": "Share Capital [Member]", "terseLabel": "Share Capital" } } }, "localname": "ShareCapitalMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareCapitalAndSharePremiumSummaryOfMovementsInCompanySShareCapitalAndSharePremiumDetails" ], "xbrltype": "domainItemType" }, "legn_ShareOptionAndRestrictedStockUnitSchemeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share option and restricted stock unit scheme.", "label": "Share Option And Restricted Stock Unit Scheme [Member]", "terseLabel": "Stock Option and Restricted Stock Unit Scheme" } } }, "localname": "ShareOptionAndRestrictedStockUnitSchemeMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_ShareOptionsExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share options exercise period.", "label": "Share Options Exercise Period", "terseLabel": "Exercise period" } } }, "localname": "ShareOptionsExercisePeriod", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "dateItemType" }, "legn_SharePremiumBeforeIssueExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share premium before issue expenses.", "label": "Share Premium Before Issue Expenses", "terseLabel": "Share premium before issue expenses" } } }, "localname": "SharePremiumBeforeIssueExpenses", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_SignificantAccountingJudgementsAndEstimatesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting judgements and estimates.", "label": "Significant Accounting Judgements And Estimates [Line Items]", "terseLabel": "Significant Accounting Judgements and Estimates [Line Items]" } } }, "localname": "SignificantAccountingJudgementsAndEstimatesLineItems", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_SignificantAccountingJudgementsAndEstimatesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting judgements and estimates.", "label": "Significant Accounting Judgements And Estimates [Table]", "terseLabel": "Significant Accounting Judgements And Estimates [Table]" } } }, "localname": "SignificantAccountingJudgementsAndEstimatesTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_SpecifiedDevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specified development milestones.", "label": "Specified Development Milestones [Member]", "terseLabel": "Specified development milestones" } } }, "localname": "SpecifiedDevelopmentMilestonesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_SpecifiedFutureDevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specified future development milestones.", "label": "Specified Future Development Milestones [Member]", "terseLabel": "Specified future development milestones" } } }, "localname": "SpecifiedFutureDevelopmentMilestonesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_SpecifiedManufacturingMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specified manufacturing milestones.", "label": "Specified Manufacturing Milestones [Member]", "terseLabel": "Specified manufacturing milestones" } } }, "localname": "SpecifiedManufacturingMilestonesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_SpecifiedNetTradeSalesMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specified net trade sales milestones.", "label": "Specified Net Trade Sales Milestones [Member]", "terseLabel": "Specified net trade sales milestones" } } }, "localname": "SpecifiedNetTradeSalesMilestonesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_SpecifiedRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specified regulatory milestones.", "label": "Specified Regulatory Milestones [Member]", "terseLabel": "Specified regulatory milestones" } } }, "localname": "SpecifiedRegulatoryMilestonesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_StatutoryBlendedIncomeTaxRate": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10010.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Statutory blended income tax rate.", "label": "Statutory Blended Income Tax Rate", "positiveLabel": "Statutory blended income tax rate", "terseLabel": "At the statutory blended income tax rate" } } }, "localname": "StatutoryBlendedIncomeTaxRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesParentheticalDetails" ], "xbrltype": "percentItemType" }, "legn_SummaryOfMovementsInContractLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of movements in contract liabilities.", "label": "Summary Of Movements In Contract Liabilities", "terseLabel": "Summary of Movements in Contract Liabilities" } } }, "localname": "SummaryOfMovementsInContractLiabilities", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "legn_SummaryOfNatureOfRelatedPartyRelationship": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of nature of related party relationship.", "label": "Summary Of Nature Of Related Party Relationship", "terseLabel": "Summary of Nature of Related Party Relationship" } } }, "localname": "SummaryOfNatureOfRelatedPartyRelationship", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "legn_SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of revenue recognized that included in contract liabilities at beginning of reporting period and performance obligation satisfied in previous periods.", "label": "Summary Of Revenue Recognized That Included In Contract Liabilities At Beginning Of Reporting Period And Performance Obligation Satisfied In Previous Periods Explanatory", "terseLabel": "Summary of Revenue Recognized That Included in Contract Liabilities at Beginning of Reporting Period and Performance Obligation Satisfied in Previous Periods" } } }, "localname": "SummaryOfRevenueRecognizedThatIncludedInContractLiabilitiesAtBeginningOfReportingPeriodAndPerformanceObligationSatisfiedInPreviousPeriodsExplanatory", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsTables" ], "xbrltype": "textBlockItemType" }, "legn_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Abstract]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://legendbiotech.com/20211231", "xbrltype": "stringItemType" }, "legn_SurchargeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surcharge rate.", "label": "Surcharge Rate", "terseLabel": "Surcharge rate" } } }, "localname": "SurchargeRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_TaxEffectOfOptionIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10160.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of option income tax expense (benefit).", "label": "Tax Effect Of Option Income Tax Expense Benefit", "terseLabel": "Option income tax benefit" } } }, "localname": "TaxEffectOfOptionIncomeTaxExpenseBenefit", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_TaxEffectsResearchAndDevelopmentCredit": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10130.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effects research and development credit.", "label": "Tax Effects Research And Development Credit", "terseLabel": "Research and development credit" } } }, "localname": "TaxEffectsResearchAndDevelopmentCredit", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10110.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax expense income at statutory blended income tax rate.", "label": "Tax Expense Income At Statutory Blended Income Tax Rate", "terseLabel": "At the statutory blended income tax rate of 28.1% (2020 and 2019: 30.1%)" } } }, "localname": "TaxExpenseIncomeAtStatutoryBlendedIncomeTaxRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_TaxLossesAndDeductibleTemporaryDifferencesNotRecognized": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10150.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax losses and deductible temporary differences not recognized.", "label": "Tax Losses And Deductible Temporary Differences Not Recognized", "terseLabel": "Tax losses and deductible temporary differences not recognized" } } }, "localname": "TaxLossesAndDeductibleTemporaryDifferencesNotRecognized", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_TaxRateEffectOfOptionIncomeTaxBenefit": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10060.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Tax rate effect of option income tax benefit.", "label": "Tax Rate Effect Of Option Income Tax Benefit", "terseLabel": "Option income tax benefit, effective tax rate" } } }, "localname": "TaxRateEffectOfOptionIncomeTaxBenefit", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "legn_TaxRateEffectOnResearchAndDevelopmentCredit": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10030.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Tax rate effect on research and development credit.", "label": "Tax Rate Effect On Research And Development Credit", "terseLabel": "Research and development credit, effective tax rate" } } }, "localname": "TaxRateEffectOnResearchAndDevelopmentCredit", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "legn_TaxRateEffectOnUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10080.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Tax rate effect on uncertain tax positions.", "label": "Tax Rate Effect On Uncertain Tax Positions", "terseLabel": "Uncertain tax positions, effective tax rate" } } }, "localname": "TaxRateEffectOnUncertainTaxPositions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "legn_TaxRateEffectOnWithholdingTaxOnInterest": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10090.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Tax rate effect on withholding tax on interest.", "label": "Tax Rate Effect On Withholding Tax On Interest", "terseLabel": "Withholding tax on interest, effective tax rate" } } }, "localname": "TaxRateEffectOnWithholdingTaxOnInterest", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "percentItemType" }, "legn_TemporaryDifferencesAndUnusedTaxLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary differences and unused tax losses.", "label": "Temporary Differences And Unused Tax Losses [Member]", "terseLabel": "Temporary Differences and Unused Tax Losses" } } }, "localname": "TemporaryDifferencesAndUnusedTaxLossesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_ThreePointZeroThreeInterestBearingLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three point zero three interest bearing loans.", "label": "Three Point Zero Three Interest Bearing Loans [Member]", "terseLabel": "3.03% Interest-Bearing Loans" } } }, "localname": "ThreePointZeroThreeInterestBearingLoansMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureInterestBearingLoansAndBorrowingsSummaryOfInterestBearingLoansAndBorrowingsDetails" ], "xbrltype": "domainItemType" }, "legn_TimeDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time deposits.", "label": "Time Deposits [Member]", "terseLabel": "Time Deposits" } } }, "localname": "TimeDepositsMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "legn_TimeDepositsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time deposits.", "label": "Time Deposits Policy [Text Block]", "terseLabel": "Time deposits" } } }, "localname": "TimeDepositsPolicyTextBlock", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "legn_TimesDeposits": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10250.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Times deposits.", "label": "Times Deposits", "terseLabel": "Time deposits" } } }, "localname": "TimesDeposits", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_TimesDepositsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Times deposits current and noncurrent.", "label": "Times Deposits Current And Noncurrent", "terseLabel": "Time deposits" } } }, "localname": "TimesDepositsCurrentAndNoncurrent", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "legn_TimesDepositsNonCurrent": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10300.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Times deposits, non-current.", "label": "Times Deposits Non Current", "terseLabel": "Time deposits" } } }, "localname": "TimesDepositsNonCurrent", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_TradeAndNotesPayables": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "order": 10120.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Trade and notes payables.", "label": "Trade And Notes Payables", "terseLabel": "Trade and notes payables", "totalLabel": "Trade and notes payables" } } }, "localname": "TradeAndNotesPayables", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesSummaryOfTradeAndNotesPayablesDetails", "http://legendbiotech.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "xbrltype": "monetaryItemType" }, "legn_TradeAndNotesPayablesLineItem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade and notes payables.", "label": "Trade And Notes Payables Line Item", "terseLabel": "Trade And Notes Payables [Line Items]" } } }, "localname": "TradeAndNotesPayablesLineItem", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_TradeAndNotesPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade and notes payables.", "label": "Trade And Notes Payables [Member]", "terseLabel": "Trade And Notes Payables" } } }, "localname": "TradeAndNotesPayablesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "legn_TradeAndNotesPayablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade and notes payables.", "label": "Trade And Notes Payables [Table]", "terseLabel": "Trade And Notes Payables [Table]" } } }, "localname": "TradeAndNotesPayablesTable", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "legn_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade Payables [Member]", "terseLabel": "Trade Payables" } } }, "localname": "TradePayablesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_TradePayablesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables, term.", "label": "Trade Payables Term", "terseLabel": "Trade payables, term" } } }, "localname": "TradePayablesTerm", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureTradeAndNotesPayablesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "legn_TradeReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade receivable.", "label": "Trade Receivable [Member]", "terseLabel": "Trade Receivables" } } }, "localname": "TradeReceivableMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "legn_TwentyNineteenTwelveTwentyFiveToTwentyTwentySevenTwelveTwentyFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty nineteen twelve twenty five to twenty twenty seven twelve twenty five.", "label": "Twenty Nineteen Twelve Twenty Five To Twenty Twenty Seven Twelve Twenty Five [Member]", "terseLabel": "2019/12/25 - 2027/12/25" } } }, "localname": "TwentyNineteenTwelveTwentyFiveToTwentyTwentySevenTwelveTwentyFiveMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandNineteenElevenTwentyNineToTwoThousandNineteenTwelveNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen eleven twenty nine to two thousand nineteen twelve nine.", "label": "Two Thousand Nineteen Eleven Twenty Nine To Two Thousand Nineteen Twelve Nine [Member]", "terseLabel": "November 29, 2019 through December 9, 2019" } } }, "localname": "TwoThousandNineteenElevenTwentyNineToTwoThousandNineteenTwelveNineMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandNineteenSevenOneToTwoThousandTwentyEightEightTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen seven one to two thousand twenty eight eight twenty nine.", "label": "Two Thousand Nineteen Seven One To Two Thousand Twenty Eight Eight Twenty Nine [Member]", "terseLabel": "2019/07/01 - 2028/08/29" } } }, "localname": "TwoThousandNineteenSevenOneToTwoThousandTwentyEightEightTwentyNineMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandNineteenTwelveThirtyOneToTwoThousandTwentyEightTwelveThirtyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen twelve thirty one to two thousand twenty eight twelve thirty.", "label": "Two Thousand Nineteen Twelve Thirty One To Two Thousand Twenty Eight Twelve Thirty [Member]", "terseLabel": "2019/12/31 - 2028/12/30" } } }, "localname": "TwoThousandNineteenTwelveThirtyOneToTwoThousandTwentyEightTwelveThirtyMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyElevenTwentyNineToTwoThousandTwentyNineElevenTwentyEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty eleven twenty nine to two thousand twenty nine eleven twenty eight.", "label": "Two Thousand Twenty Eleven Twenty Nine To Two Thousand Twenty Nine Eleven Twenty Eight [Member]", "terseLabel": "2020/11/29 - 2029/11/28" } } }, "localname": "TwoThousandTwentyElevenTwentyNineToTwoThousandTwentyNineElevenTwentyEightMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyOneElevenNineteenToTwoThousandThirtyElevenEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one eleven nineteen to two thousand thirty eleven eighteen.", "label": "Two Thousand Twenty One Eleven Nineteen To Two Thousand Thirty Eleven Eighteen [Member]", "terseLabel": "2021/11/19 - 2030/11/18" } } }, "localname": "TwoThousandTwentyOneElevenNineteenToTwoThousandThirtyElevenEighteenMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyOneZeroNineZeroOneToTwoThousandThirtyZeroEightThirtyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one zero nine zero one to two thousand thirty zero eight thirty one.", "label": "Two Thousand Twenty One Zero Nine Zero One To Two Thousand Thirty Zero Eight Thirty One [Member]", "terseLabel": "2021/09/01 - 2030/08/31" } } }, "localname": "TwoThousandTwentyOneZeroNineZeroOneToTwoThousandThirtyZeroEightThirtyOneMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyOneZeroSixZeroFiveToTwoThousandThirtyZeroSixZeroFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one zero six zero five to two thousand thirty zero six zero four.", "label": "Two Thousand Twenty One Zero Six Zero Five To Two Thousand Thirty Zero Six Zero Four [Member]", "terseLabel": "2021/06/05 - 2030/06/04" } } }, "localname": "TwoThousandTwentyOneZeroSixZeroFiveToTwoThousandThirtyZeroSixZeroFourMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyTwoEightTwentySevenToTwoThousandThirtyOneEightTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty two eight twenty seven to two thousand thirty one eight twenty six.", "label": "Two Thousand Twenty Two Eight Twenty Seven To Two Thousand Thirty One Eight Twenty Six [Member]", "terseLabel": "2022/08/27 \u2013 2031/08/26" } } }, "localname": "TwoThousandTwentyTwoEightTwentySevenToTwoThousandThirtyOneEightTwentySixMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyTwoThreeTwentyNineToTwoThousandThirtyOneThreeThirtyEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty two three twenty nine to two thousand thirty one three thirty eight.", "label": "Two Thousand Twenty Two Three Twenty Nine To Two Thousand Thirty One Three Thirty Eight [Member]", "terseLabel": "2022/03/29 \u2013 2031/03/28" } } }, "localname": "TwoThousandTwentyTwoThreeTwentyNineToTwoThousandThirtyOneThreeThirtyEightMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_TwoThousandTwentyZeroSevenZeroTwoToTwoThousandTwentyNineZeroSevenZeroOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty zero seven zero two to two thousand twenty nine zero seven zero one.", "label": "Two Thousand Twenty Zero Seven Zero Two To Two Thousand Twenty Nine Zero Seven Zero One [Member]", "terseLabel": "2020/07/02 - 2029/07/01" } } }, "localname": "TwoThousandTwentyZeroSevenZeroTwoToTwoThousandTwentyNineZeroSevenZeroOneMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeSummaryOfExercisePricesAndExercisePeriodsOfShareOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "legn_USAndNonUSTerritoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US and Non-US territories.", "label": "U S And Non U S Territories [Member]", "terseLabel": "US and Non-US Territories" } } }, "localname": "USAndNonUSTerritoriesMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "legn_USDollarStrengthensAgainstEURMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US$ strengthens against EUR.", "label": "U S Dollar Strengthens Against E U R [Member]", "terseLabel": "US$ Strengthens Against EUR" } } }, "localname": "USDollarStrengthensAgainstEURMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "legn_USDollarStrengthensAgainstRMBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US$ strengthens against RMB.", "label": "U S Dollar Strengthens Against R M B [Member]", "terseLabel": "US$ Strengthens Against RMB" } } }, "localname": "USDollarStrengthensAgainstRMBMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "legn_USDollarWeakensAgainstEURMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US$ weakens against EUR.", "label": "U S Dollar Weakens Against E U R [Member]", "terseLabel": "US$ Weakens Against EUR" } } }, "localname": "USDollarWeakensAgainstEURMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "legn_USDollarWeakensAgainstRMBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US$ weakens against RMB.", "label": "U S Dollar Weakens Against R M B [Member]", "terseLabel": "US$ Weakens Against RMB" } } }, "localname": "USDollarWeakensAgainstRMBMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesSummaryOfSensitivityToReasonablyPossibleChangeInExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "legn_UncertainTaxPositions": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10180.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Uncertain tax positions.", "label": "Uncertain Tax Positions", "terseLabel": "Uncertain tax positions" } } }, "localname": "UncertainTaxPositions", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_UpfrontFeesRecognizedAsRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront fees recognized as revenue.", "label": "Upfront Fees Recognized As Revenue", "terseLabel": "Upfront fees recognized as revenue" } } }, "localname": "UpfrontFeesRecognizedAsRevenue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "legn_WarrantLiabilityAssessed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability assessed.", "label": "Warrant Liability Assessed", "terseLabel": "Warrant liability assessed", "verboseLabel": "Issuance of the warrant liability" } } }, "localname": "WarrantLiabilityAssessed", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityScheduleOfMovementOfWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "legn_WarrantLiabilityFairValueLossRecorded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrant liability fair value loss recorded.", "label": "Warrant Liability Fair Value Loss Recorded", "terseLabel": "Warrant liability fair value loss recorded in profit or loss", "verboseLabel": "Fair value loss of the warrant liability" } } }, "localname": "WarrantLiabilityFairValueLossRecorded", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityScheduleOfMovementOfWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "legn_WarrantsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants liability member.", "label": "Warrants Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantsLiabilityMember", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsByCategorySummaryOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "legn_WeightedAverageSharePriceUsedInShareOptionFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average share price used in share option fair value.", "label": "Weighted Average Share Price Used In Share Option Fair Value", "terseLabel": "Weighted average share price used in share option fair value valuation model (US$ per share)" } } }, "localname": "WeightedAverageSharePriceUsedInShareOptionFairValue", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureShareOptionSchemeAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "legn_WithholdingTaxOnInterest": { "auth_ref": [], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails": { "order": 10190.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Withholding tax on interest.", "label": "Withholding Tax On Interest", "terseLabel": "Withholding tax on interest" } } }, "localname": "WithholdingTaxOnInterest", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxSummaryOfReconciliationOfTaxExpenseApplicableToLossBeforeTaxAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "legn_WithholdingTaxPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Withholding tax percentage.", "label": "Withholding Tax Percentage", "terseLabel": "Withholding tax percentage" } } }, "localname": "WithholdingTaxPercentage", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "legn_WithholdingTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Withholding tax rate.", "label": "Withholding Tax Rate", "terseLabel": "Withholding tax rate" } } }, "localname": "WithholdingTaxRate", "nsuri": "http://legendbiotech.com/20211231", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureCashAndCashEquivalentsTimeDepositsAndPledgedDepositsSummaryOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r309", "r310", "r311", "r312", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r309", "r310", "r311", "r312", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureDeferredTaxAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationAdditionalInformationDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfNonCurrentAssetsDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureOperatingSegmentInformationSummaryOfRevenueFromExternalCustomersDetails", "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "New Jersey" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r314" ], "calculation": { "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails": { "order": 10010.0, "parentTag": "legn_OtherIncomeAndGains", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income 1", "totalLabel": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRevenueOtherIncomeAndGainsOtherIncomeAndGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLeasingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.", "label": "Payments For Leasing Costs", "terseLabel": "Consideration under lease agreement" } } }, "localname": "PaymentsForLeasingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://legendbiotech.com/20211231/taxonomy/role/DisclosureWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_b&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_c&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_f&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_j&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r106": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126_a&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "129", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_129_a&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "88", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_88&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_b&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "136", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_136&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "138", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "30", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_a&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r179": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r181": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r182": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r183": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r184": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r185": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r186": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r187": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r188": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r189": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r191": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_c&doctype=Standard", "URIDate": "2021-03-24" }, "r192": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r193": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r194": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r195": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r196": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r197": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r198": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard", "URIDate": "2021-03-24" }, "r199": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r200": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24" }, "r201": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2021-03-24" }, "r202": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_b&doctype=Standard", "URIDate": "2021-03-24" }, "r203": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_c&doctype=Standard", "URIDate": "2021-03-24" }, "r204": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2021-03-24" }, "r205": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r206": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r207": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r208": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r209": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24" }, "r210": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24" }, "r211": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2021-03-24" }, "r212": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2021-03-24" }, "r213": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24" }, "r214": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r215": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r216": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r217": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r218": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24" }, "r219": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2021-03-24" }, "r220": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r221": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2021-03-24" }, "r222": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r223": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r224": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r225": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r226": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r227": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r228": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24" }, "r229": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r230": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r231": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r232": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r233": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2021-03-24" }, "r234": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r235": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r236": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "IG23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r237": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r238": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r239": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r240": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24" }, "r241": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r242": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r243": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r244": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r245": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r246": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r247": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r248": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r249": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2021-03-24" }, "r250": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r251": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r252": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r253": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r254": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r255": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "40", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2021-03-24" }, "r256": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r257": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24" }, "r258": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r259": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r260": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2021-03-24" }, "r261": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2021-03-24" }, "r262": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2021-03-24" }, "r263": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r264": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11E", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11E&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r265": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r266": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG20C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r267": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG20D", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r268": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r269": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG32&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r270": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2021-03-24" }, "r271": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r272": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r273": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r274": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r275": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r276": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r277": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r278": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r279": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r280": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r281": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r282": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r283": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r284": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24" }, "r285": { "IssueDate": "2021-01-01", "Name": "SIC", "Number": "29", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=SIC&num=29&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r286": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r287": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r288": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r289": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r290": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24" }, "r291": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24" }, "r292": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r293": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r294": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r295": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r296": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r297": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r298": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24" }, "r299": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r300": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r301": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r302": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r303": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r304": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r305": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r306": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r307": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r308": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r326": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r327": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r328": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r329": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r330": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r331": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r332": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r333": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r334": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r335": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r34": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_c&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_c&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }